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Abstract 
Multiphoton microscopy (MPM) has become increasingly popular and widely used in both 
basic and clinical liver studies over the past few years. The fluorescence lifetime imaging 
(FLIM) can be coupled with MPM to add additional quantitation and specificity to the 
detection of endogenous fluorescent species in the liver as well as exogenous molecules, 
nanoparticles and therapeutic cells that applied to the liver both in vitro and in vivo. These 
technologies provide deep penetration of live tissues with less photobleaching and 
phototoxicity, and help our better understanding of the cellular morphology, 
microenvironment, immune responses and spatiotemporal dynamics of drugs and 
therapeutic cells in the healthy and diseased liver.  
 
Taking advantages of MPM-FLIM, the aim of this project is to develop novel optical 
imaging methods for diagnosis and prediction of treatment response in liver diseases. The 
main achievements obtained in this thesis are listed as below: 
 
(1) Conventional histology with light microscopy is essential in the diagnosis of most liver 
diseases. Recently, a concept of real-time histology with optical biopsy has been 
advocated. Live mice livers (normal, with fibrosis, steatosis, hepatocellular carcinoma and 
ischemia-reperfusion injury) were imaged by MPM-FLIM for stain-free real-time histology. 
The acquired MPM-FLIM images were compared with conventional histological images. 
MPM-FLIM imaged subsurface cellular and subcellular histopathological hallmarks of live 
liver in mice models at high resolution. Additional information such as distribution of 
stellate cell associated autofluorescence and fluorescence lifetime changes was also 
gathered by MPM-FLIM simultaneously, which cannot be obtained from conventional 
histology. MPM-FLIM could visualise the cell morphology and microenvironment changes 
in diseased livers without conventional biopsy or administration of fluorescent dyes.  
 
(2) Oxidative stress reflects an imbalance between reactive oxygen species (ROS) and 
antioxidants, which has been reported as an early unifying event in the development and 
progression of various diseases and as a direct and mechanistic indicator of treatment 
response. A transition-metal complex-based sensing platform was developed for in vivo 
MPM-FLIM imaging of oxidative stress at a single cell resolution. By combining 
fluorescence intensity and fluorescence lifetime imaging, this sensing platform accurately 
localised ROS and glutathione (GSH) within the liver, and quantified their changes during 
liver injury. This precedes changes in conventional biochemical and histological 
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assessments. Importantly, the optical oxidative stress index (OSI), expressed as the 
fluorescence intensity ratio of ROS and GSH probes, has significant implications for 
sensitive, spatially configured and quantitative assessment of metabolic status and drug 
response, which could reveal mechanistic insights and accelerate drug development 
studies. 
 
(3) Although mesenchymal stem cells (MSCs) present a promising tool in cell therapy for 
the treatment of liver cirrhosis, the in vivo distribution of administered MSCs has still been 
poorly understood, which hampers the precise prediction and evaluation of their 
therapeutic efficacy. The spatiotemporal disposition of administered MSCs in the liver was 
directly visualized using MPM and the cell quantity was assessed using flow cytometry. A 
physiologically based kinetic model was developed to characterise the in vivo distribution 
of MSCs. This model was further validated with multiple external datasets, indicating 
potential inter-route and inter-species predictive capability. The results suggest that the 
targeting efficiency of MSCs is determined by the lung retention and interaction between 
MSCs and target organs, including cell arrest, depletion and release. By adapting specific 
parameters, this model can be easily applied to abnormal conditions or other types of 
circulating cells for designing treatment protocols and guiding future experiments. 
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Chapter 1  
 
Introduction 
 
1.1 Significance of real-time optical imaging of the liver 
        Humans always want to see farther and better. “...The medical uses of optical 
imaging are revolutionising medicine; optical imaging is undergoing explosive growth 
fuelled by advances in high-sensitivity detectors, improved optics, and developments 
in molecular biology…” [1]. Because liver is the key metabolic organ of the body and 
is critical for survival, various imaging technologies are now used in the screening 
and surveillance of liver pathology, such as ultrasound for hepatocellular carcinoma 
in patients at high risk. Computed tomography (CT) and magnetic resonance 
imaging (MRI) are increasingly able to provide a sensitive macroscopic view of the 
liver’s anatomy and physiology, enabling early liver disease detection and 
characterisation. Emerging newer systems that based in light excitation and 
detection of bioluminescence, fluorescence, reflectance and sound (photoacoustic 
imaging) enable function, metabolic processes and molecular information to be 
defined with high resolution [2]. The combination of the light based systems, such as 
positron emission tomography (PET), with CT or MRI scans can lead to better 
cancer and metastasis diagnosis [3].  
        The light based systems, multi-photon (MPM) and confocal laser scanning 
microscopy (CLSM) and fluorescence lifetime imaging (FLIM), now provide mini-
invasive quantitative imaging of fluorescent molecules in in situ and in vivo biological 
tissues and organs - in space (three dimensions), in time, in spectra, in lifetime and 
in fluorescence anisotropy (total of 7 dimensions). These techniques allow dynamic 
and functional cellular and subcellular imaging in vivo and have been used widely in 
neuroscience for observation of neuronal plastic changes, measuring ionized-
calcium dynamics in brain [4] and imaging neurovascular bundle [5], in immunology 
[6] for imaging of heterogeneous immune process at cellular and molecular levels [7], 
in cancer research for studying angiogenesis [8] and metastasis [9]. Currently, the 
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application of optical imaging in the liver is limited. The main aim of this project is to 
systemically investigate the utility of MPM-FLIM for diagnosis and prediction of 
treatment response in liver diseases. 
1.2 Objectives of this project 
        The overall aim of this project is to develop novel optical imaging methods for 
diagnosis and prediction of treatment response in liver diseases. The specific aims 
include: 
 To develop stain-free and real-time histology of live liver in common liver 
diseases using MPM-FLIM. (main work of chapter 3) 
 To predict treatment response during liver injury by quantification of cellular 
oxidative stress using MPM-FLIM. (main work of Chapter 4)  
 To elucidate the in vivo fate of administered mesenchymal stem cells (MSCs) for 
the treatment of liver diseases by direct visualisation and mathematic modelling. 
(main work of Chapter 5) 
1.3 Achievements of this project 
        This thesis is written according to the guidelines of the University of 
Queensland. The outcomes of this PhD thesis are presented in the form of journal 
publications, and the chapters are presented in the following sequence: 
 Chapter 2 gives a comprehensive overview on the principles, opportunities, 
applications and limitations of MPM-FLIM in hepatology.  
 Chapter 3 demonstrates that MPM-FLIM is able to visualise the cellular 
morphology and microenvironment of live livers in common liver diseases. 
 Chapter 4 presents a two-photon dual sensing platform for in vivo imaging of 
oxidative stress at single cell-level resolution, and reveals that changes in 
oxidative stress of hepatocytes precede changes in conventional biochemical 
and histological assessments in liver injury. 
 Chapter 5 develops a mathematical model to characterise and predict the in vivo 
kinetics of administered MSCs for the treatment of liver cirrhosis based on direct 
visualisation of cell spatiotemporal disposition by MPM. 
 Chapter 6 summarises the achievements of the whole project, and presents 
outlooks of MPM-FLIM in the biomedical field. 
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Chapter 2  
Literature review: visualising liver 
anatomy, physiology and pharmacology 
using multiphoton microscopy 
 
 
 
 
 
2.1 Synopsis 
        This chapter summarises the principles, opportunities, applications and 
limitations of multiphoton microscopy in hepatology. The information discussed in 
this chapter is essential to the development of real-time optical imaging strategies for 
the liver in the following chapters. 
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        The review entitled, “Visualizing liver anatomy, physiology and pharmacology 
using multiphoton microscopy” has been published by Journal of Biophotonics, 2017; 
10(1):46-60. The manuscript, figures and tables have been adjusted to fit the overall 
style of the Thesis and incorporated as this chapter. 
2.2 Abstract 
Multiphoton microscopy (MPM) has become increasingly popular and widely 
used in both basic and clinical liver studies over the past few years. This technology 
provides insights into deep live tissues with less photobleaching and phototoxicity, 
which helps us to better understand the cellular morphology, microenvironment, 
immune responses and spatiotemporal dynamics of drugs and therapeutic cells in 
the healthy and diseased liver. This review summarises the principles, opportunities, 
applications and limitations of MPM in hepatology. A key emphasis is on the use of 
fluorescence lifetime imaging (FLIM) to add additional quantification and specificity to 
the detection of endogenous fluorescent species in the liver as well as exogenous 
molecules and nanoparticles that are applied to the liver in vivo. We anticipate that in 
the near future MPM-FLIM will advance our understanding of the cellular and 
molecular mechanisms of liver diseases, and will be evaluated from bench to 
bedside, leading to real-time histology of human liver diseases.  
Key Words: Multiphoton microscopy; Fluorescence lifetime imaging; Liver; 
Morphology, Function; Diseases 
 
2.3 Introduction 
        Liver is one of the most important metabolic organs of vertebrates with multiple 
functions. It receives oxygenated blood from the heart via the hepatic artery, and 
nutrient-rich blood from the gastrointestinal tract via the portal vein (Fig. 2.1A). The 
blood flows through liver sinusoids (Fig. 2.1B, terminal vessels between hepatocyte 
cords and lined with Kupffer cells and endothelial cells), empties into the central vein, 
and exits the liver from hepatic veins. Hepatocytes make up 70-85% of the liver’s cell 
population. They are the key functional liver cells with important roles in metabolic, 
secretory and endocrine functions [1, 2]. Kupffer cells, another type of liver cells, are 
specialized macrophages in the liver located on the walls of the liver sinusoids [3]. 
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Hepatic stellate cells (HSC) are pericytes located in the space of Disse, which is 
located between the hepatocytes and sinusoidal endothelium. Quiescent HSCs can 
be activated in response to liver damage, leading to collagen formation, fibrosis or 
cirrhosis [4]. Bile is secreted by hepatocytes, and drained into biliary ductules, which 
are lined with epithelial cells, then leaves the liver from the bile duct [3]. 
 
Figure 2.1 Structure of the liver. (A) Macrostructure of the liver. (B) Microscopic 
structure of liver sinusoid in hepatic lobules. (C) Representative TPEF image of the 
liver, recorded at λExc/λEm: 740/350 to 650 nm. (D) Representative FLIM of the liver, 
recorded at λExc/λEm: 740/350 to 450 nm. A: Hepatic artery; P: Portal vein; V: Hepatic 
veins; H: Hepatocyte; E: Endothelial cell; S: Sinusoid; K: Kupffer cell; D: Space of 
Disse; HSC: Hepatic stellate cell (arrow). Reproduced with permission [2]. 2015, The 
Royal Society of Chemistry. 
 
      Conventional optical illumination techniques are insufficient to precisely describe 
the complex internal three-dimensional structure, heterogeneous cell populations 
and the dynamics of biological processes of the liver. The need for better imaging 
tools has triggered a renaissance in the development of optical-microscopy 
instrumentation in the past three decades. In 1990, two-photon microscopy, later 
also referred to as multiphoton microscopy (MPM), was pioneered by Denk et al. at 
Cornell University [5]. This important invention enabled unprecedented quantitative 
deep imaging of the liver down to the molecular level. Fluorescence lifetime imaging 
(FLIM), first developed in 1989, was soon used in MPM in 1990s [6]. This imaging 
technique can provide detailed information about the liver microenvironment which 
cannot be revealed by microscopy using fluorescence intensity. The applications of 
MPM and FLIM in hepatology have been discussed in several review articles. These 
papers focused on specific areas of MPM such as defining liver functions [7], 
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imaging liver cancers [8], or just provided a general description of intravital imaging 
of the liver [9]. Although numerous techniques, fluorescent dyes and proteins that 
favor MPM have been proposed, there are only scattered reports on the detailed 
applications and limitations of MPM and FLIM in hepatology. The scope of this 
comprehensive review is to first summarize the principles and advantages of MPM 
for imaging the liver systematically. Subsequently, we will evaluate the application of 
MPM in visualizing anatomy, defining functions and studying pharmacology of the 
liver, and will highlight the use of FLIM. The information discussed in this review 
would be useful for the development of in vivo imaging strategies for the liver, as 
pointed out in the final section. 
2.4 Principles and advantages of MPM for imaging the liver 
2.4.1 MPM 
Fluorescence is the emission of light by a substance after absorbing light or other 
electromagnetic radiation. Usually the absorbed light has a shorter wavelength and 
higher energy than the emitted light. This is known as single-photon fluorescence 
that is applied in traditional fluorescence microscopy. In contrast, MPM uses pulsed 
longer-wavelength light to excite fluorophores in the specimen being observed [5, 
10]. Two photons must meet the fluorophores simultaneously (within 10−18 s) in 
order to excite a fluorophore to emit a fluorescence photon with shorter wavelength 
and higher energy. A typical optical principle of MPM is shown in Fig. 2.2A. MPM is 
considered as a revolutionary development in biological imaging because the longer-
wavelength and lower-energy excitation light reduces photodamage and increases 
penetration depth, allowing imaging of living specimens [11]. Unlike confocal 
microscopes, MPM does not contain pinhole apertures, allowing the detector to be 
placed closer to the objective to optimize collection of scattered light, and further 
enhancing the imaging depth. 
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Figure 2.2 Typical optical principle of multiphoton systems and imaging modalities. 
(A) A typical MPM uses a raster scanning system to control the beam and a dichroic 
is used to separate TPEF from the excitation light and direct this fluorescence to a 
single-element detector such as a photomultiplier tube (PMT). (B) Energy level 
diagrams of TPEF, SHG and CARS imaging modalities. L: lens; SM: scan mirror; O: 
objective; S0: the ground energy state; S1: the excited state; Sh: the higher virtual 
state. Reproduced with permission [10, 12]. 2013, Nature Publishing Group. 2010, 
Elsevier. 
2.4.2 Imaging modality of MPM 
          As shown in Fig. 2.2B, MPM can excite and detect nonlinear signals including 
two-photon excited fluorescence (TPEF), second harmonic generation (SHG) and 
coherent anti-Stokes Raman scattering (CARS) [13]. The concept of TPEF is based 
on the idea mentioned above that two photons of lower energy can excite an 
electron into a state with higher energy, from which it can decay and emit a shorter-
wavelength light. Each photon carries approximately half the energy necessary to 
excite the fluorophore [5]. The most commonly used fluorophores in MPM have 
excitation spectra in the range of 400-500 nm, whereas the laser used to excite the 
TPEF lies in the 700~1000 nm range. As shown in Table 2.1, a number of 
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endogenous molecules in the liver can generate fluorescence, which is a hindrance 
of traditional fluorescence microscopy, yet is used as an advantage in TPEF imaging 
[14]. The metabolic coenzymes nicotinamide adenine dinucleotide hydride (NADH) is 
a respiratory substrate for complex I of the mitochondrial electron transport chain, 
which is an endogenous fluorophore in the cytoplasm of hepatocytes. As the 
fluorescence excitation, emission, and lifetime of NADH and NADPH overlap, these 
two molecules are usually measured together by MPM coupled with FLIM (MPM-
FLIM) and referred to as NAD(P)H [15]. TPEF images of NAD(P)H in the liver can 
provide basic information of liver structure. Because NAD+, the oxidized form of 
NAD(P)H, has no fluorescence, changes in the fluorescence intensity of NAD(P)H 
can provide valuable information regarding cell metabolisms. Flavin adenine 
dinucleotide (FAD) which is only fluorescent in the oxidative states, can provide 
further information of the cellular redox state [14, 16]. The most common optical 
method for metabolic imaging is the “redox ratio,” which is the ratio of the 
fluorescence intensity of FAD and NAD(P)H. The redox ratio is sensitive to changes 
in the cellular metabolic rate and vascular oxygen supply [14, 16]. A decrease in the 
redox ratio or the fluorescence intensity of NAD(P)H is usually observed in cancer 
cells or injured cells. 
        In SHG, photons with the same frequency interact with a nonlinear substance 
and generate new photons with half the wavelength of the initial photons [17]. Since 
SHG is an even-order nonlinear non-absorption process, fluorophore is not required 
in the specimen. Only highly ordered structures without inversion symmetry are 
capable of emitting SHG light. Collagen, a sensitive indicator of liver fibrosis, is one 
such structure.  
        CARS is a third-order nonlinear optical process involving multiple types of 
photons: a pump photon, a Stokes photon and a probe photon. These three photons 
interact with the sample, and generate a coherent optical signal at the anti-Stokes 
frequency. This signal will be enhanced when the frequency difference between the 
pump and the Stokes photons coincides with the frequency of a Raman resonance 
[18]. CARS imaging is intrinsic and specific to molecular vibration, such as aliphatic 
C-H bonds of lipids. Thus it is ideal for detecting intracellular fat vacuoles in fatty liver 
tissues.   
2.4.3 FLIM 
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        The fluorescence lifetime is the mean time a fluorophore remains in the excited 
state before emitting a photon (fluorescence) and returning to the initial ground 
energy state. FLIM has been used as an important imaging technique in MPM, which 
constructs a spatial distribution map of fluorescence lifetimes from a fluorescent 
specimen [19]. The lifetime of the fluorophore signal, rather than its intensity, is used 
to create the image. Fig. 2.1D shows an example of FLIM image of normal mouse 
liver. This technique has the advantage of differentiating various endogenous and 
exogenous fluorophores in the liver tissue based on their unique lifetimes. Table 2.1 
shows the lifetimes of major endogenous fluorophores in the normal liver. Lifetime 
changes of exogenous fluorophores usually reflect drug-interactions or protein-
interactions, while those changes of endogenous fluorophores reflect changes in 
liver microenvironment, which cannot be revealed by microscopy using fluorescence 
intensity.  
        A common application of FLIM in the liver is to measure the fluorescence 
lifetime of NAD(P)H. NAD(P)H can exist as free or protein-bound molecules, which 
have similar excitation and emission wavelengths, but can be distinguished by their 
distinct fluorescence lifetimes. Protein-bound NAD(P)H mainly locates in 
mitochondrial membrane, and produces adenosine triphosphate (ATP) in aerobic 
conditions, while free NAD(P)H is located in the cytoplasm, involving in ATP 
synthesis without oxygen in glycolysis. The relative contribution of protein-bound 
NAD(P)H decrease in hypoxia, mainly because cellular respiration is shifted to 
glycolysis, producing ATP in anaerobic conditions [20, 21]. The changes of lifetimes 
of free and protein-bound NAD(P)H also indicate altered metabolic state, as is 
typically observed in cell differentiation, apoptosis and necrosis [20]. 
2.5 Imaging liver anatomy and diagnosing liver diseases  
MPM has been applied in diagnosis of almost all types of liver diseases in 
human beings and animals. Liver fibrosis, cancer and steatosis are the most widely 
studied liver diseases using MPM, which will be discussed in detail below. In 
addition, the MPM optical diagnostic features for hepatic ischemia-reperfusion (I/R) 
injury were reported to include reduced fluorescence and cellular vacuolation of 
hepatocytes, and heterogeneous spread of damage over the liver [22]. 
11 
 
Acetaminophen (APAP) induced liver injury [23] and hepatitis C virus infections [24] 
have also been visualized using fluorescent dyes or sensors for MPM.   
2.5.1 Normal liver 
        The capsule of the liver, known as Glisson’s capsule, is a fibrous connective 
membrane mainly composed of collagen and elastin fibers. It encompasses the 
hepatic parenchyma, and contributes significantly to the global mechanical behavior 
of the liver. MPM has been used to characterize the shape, geometry and 
microstructure arrangement of the capsule using TPEF and SHG [25, 26]. The 
obtained images revealed that the collagen/elastin ratio increases from the inner to 
the outer surface of the liver capsule. The microstructure and strain fields of the 
capsule present heterogeneity among different layers. Reorientation occurs in fiber 
layers from the inner to the outer surface of the liver capsule. 
The cellular structure of liver can be imaged as deep as 250 μm below the liver 
capsule by MPM. As shown in Fig. 2.1, 2.3 and 2.4, hepatocyte cords with bright 
autofluorescence of NAD(P)H are separated by the blood-filled dark sinusoids in 
TPEF imaging. The stellate cells are smaller in size but have strong vitamin A-
associated autofluorescence and a longer lifetime than that of NAD(P)H [21]. 
Fenestrations are transcellular pores in endothelial cells that facilitate transfer of 
substrates between blood and the extravascular compartment. Liver sinusoidal 
endothelial cells could be stained by 6-lauroyl-2-dimethylaminonaphthalene 
(LAURDAN) to visualize the number and size of fenestrations using MPM [27]. 
Recently, more specific fluorescence-conjugated antibodies (such as anti-
PECAM1/CD31 or anti-VCAM-1/CD106) have been developed to stain viable liver 
sinusoidal endothelium [9, 28].  
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Figure 2.3 MPM-FLIM and conventional histopathological images of liver in healthy 
mice, Mdr2−/− mice and mice with CCl4 induced liver fibrosis at low magnification 
(10×) (scale bar: 80 μm). Autofluorescence intensity image was recorded at λExc/λEm: 
740/350 to 650 nm. Autofluorescence and SHG intensity image was recorded at 
λExc/λEm: 800/350 to 650 nm. Pseudocolored fluorescence lifetime image for NADH 
(τm: 0-2500 ps; blue-green-red) was recorded at λExc/λEm: 740/350 to 450 nm. 
Pseudocolored fluorescence lifetime image for NADH and collagen (τm: 0-2500 ps; 
blue-green-red) was recorded at λExc/λEm: 800/350 to 450 nm. Conventional 
histological images were collected on Van Gieson’s stained section. Opened arrows 
indicate collagen; asterisks indicate bile duct; curved arrow indicates bridges formed 
by stellate cells; filled arrows indicate postsinusoidal venules; and arrow head 
indicates injury of hepatocytes. MPM-FLIM images of unfixed live livers were 
collected within 30 min after surgical procedures started, and 2 days after the last 
CCl4 injection. Reproduced with permission [21]. 2015. OSA Publishing. 
2.5.2 Liver fibrosis 
In liver fibrosis, injury of hepatocytes can be observed as reduced fluorescence 
of NAD(P)H in TPEF imaging (Fig. 2.3 and 2.4) [21]. Moreover, FLIM shows 
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changes in cellular metabolic pathways as indicated by the decrease of lifetimes of 
free and protein-bound NAD(P)H, and contribution of protein-bound NAD(P)H (Fig. 
2.4). The livers of mice receiving CCl4 for 5 weeks showed signs of postsinusoidal 
venules. HSCs can be detected using real-time histology by their distinct vitamin A-
associated autofluorescence. Inhomogeneous distribution of stellate cells was found 
in a mouse model of chronic chemical hepatic injury and advanced liver fibrosis [21]. 
The stellate cells accumulated in centrilobular region around central veins, and 
reduced in midzonal regions. The regional redistribution of stellate cells formed 
bridges between postsinusoidal venules in some liver lobules. The morphology and 
distribution of stellate cells imaged by MPM provide valuable information about 
cellular microenvironment during development of liver fibrosis, which cannot be 
obtained from conventional histology. 
SHG imaging has been performed on liver biopsies taken from patients with liver 
fibrosis or cirrhosis [21, 29], rodents with CCl4 induced chronic injury and fibrosis 
[21], and cholangitis and biliary fibrosis (Mdr2−/− and bile duct ligation) [21, 29]. 
MPM can clearly reveal the increase of the collagen amount during fibrosis 
progression and offer the possibility of an accurate characterization of fibrosis 
without specific staining. As shown in Figure 3, collagen deposition was obvious in 
the centrilobular region and pseudolobular formation was evident in in CCl4 induced 
fibrotic liver. While the livers with biliary fibrosis of 20-week-old Mdr2−/− mice 
showed intercellular fibrosis, especially around the medium sized to large bile ducts 
of the periportal region. Two quantification systems, Fibro-C-Index [29] and Fibrosis-
SHG index (Fig. 2.5) [12] have been developed for the assessment of liver fibrosis 
using MPM. Both systems have been compared and validated by pathological 
examination, indicating the high reliability and sensitivity for potential application of 
MPM in clinical diagnosis of liver fibrosis. Since collagen SHG response is effectively 
instantaneous [30], the mean lifetimes decreased significantly in fibrotic liver at 
excitation of 800 nm (containing both NADH and collagen signals), allowing the 
discrimination from normal liver (Fig. 2.3). MPM-FLIM would be a powerful tool 
providing realtime histology which combines morphology and quantitative evaluation 
of liver fibrosis simultaneously. 
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Figure 2.4 MPM-FLIM and conventional histopathological images of the mouse liver 
in health and disease at high magnification (40×) (Scale bar: 20 μm.). 
Autofluorescence intensity image was recorded at λExc/λEm: 740/350 to 650 nm. 
Pseudocolored fluorescence lifetime image (τm: 0-2500 ps; blue-green-red) was 
recorded at λExc/λEm: 740/350 to 450 nm. Black arrow indicates stellate cells 
associated autofluorescence; white arrows indicate cellular necrosis; and opened 
arrow indicates intracellular fat vacuole. MPM-FLIM images of unfixed live livers 
were collected within 30 min after surgical procedures started. Conventional 
histological images were collected on H&E stained section. Reproduced with 
permission [21]. 2015. OSA Publishing. 
 
 
 
15 
 
 
Figure 2.5 Collagen quantification in human liver fibrosis using MPM. (a-d) 
TPEF/SHG images of the fibrosis (F0-Metavir grade) and cirrhotic (F4-Metavir grade) 
liver samples from surgical (a) and needle biopsies (b). F-Metavir grades have been 
determined by a pathologist using the Metavir scoring system from conventional 
histology. Red color represents the TPEF signal of hepatocytes and green color 
represents the SHG signal of collagen fibers. Laser intensity was set at 100 mW and 
wavelength was fixed at 810 nm. Scale bar: 1 mm. (e) Standardized Fibrosis-SHG 
indexes determined for each F-Metavir stage in 46 surgical and 73 needle biopsies. 
Histograms indicate the average indexes ±SEM after normalization. Reproduced 
with permission [12]. 2010, Elsevier. 
2.5.3 Liver cancer 
The most common type of primary liver cancer is hepatocellular carcinoma 
(HCC). The MPM optical diagnostic features for HCC have been established and 
validated in different studies [21, 31]. High-resolution MPM images have clearly 
demonstrated extensive cell heterogeneity characterized by irregular size and shape, 
increased nuclear to cytoplasmic ratio, decreased autofluorescence of NAD(P)H, 
central necrosis and intercellular collagen in HCC (Fig. 2.4). Yan et al. performed a 
pilot preclinical study investigating 224 surgical specimens including benign and 
malignant liver lesions such as hemangioma, focal nodular hyperplasia, HCC, 
cholangiocarcinoma, and colorectal cancer liver metastases. They found that MPM is 
able to diagnose liver cancer and differentiate benign and malignant liver lesions with 
high sensitivity, specificity and accuracy [31]. 
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In FLIM images, the cellular lifetimes of free and protein-bound NAD(P)H, and 
contribution of protein-bound NAD(P)H significantly decreased in HCC, which is 
consistent with hypoxia and the increased levels of glycolysis in neoplastic cells (Fig. 
2.4). In poorly-differentiated HCC sections, an increased cellular lifetime of red 
fluorescent pigments including porphyrins, biliverdins and bilirubins, and scattered 
short-lifetime spots can also be detected non-uniformly, which may represent the 
inflammation-induced infiltrated leukocytes [32]. Thus, MPM-FLIM has the potential 
to become a powerful clinical tool in the future to perform real-time diagnosis of liver 
cancer and differentiation of benign and malignant liver lesions. 
2.5.4 Liver steatosis 
In liver with steatosis, black intracellular fat vacuole can be detected as spots 
with significantly reduced fluorescence of NAD(P)H (darker than the nuclei) in TPEF 
images (Fig. 2.4) [21]. The cytoplasm of hepatocytes has a sponge-like appearance 
because of numerous small black intracellular fat inclusions in mice after feeding a 
high fat diet for 14 days (Fig. 2.4). Compared to TPEF imaging, CARS imaging can 
specifically visualize fat droplets in fresh liver samples and extract the fat content 
through image analysis [33]. Similarly to the way using SHG to quantify the collagen 
amount in the fibrotic liver, CARS imaging has been used to quantitatively assess 
the fat in rat livers with steatosis [33]. The content of hepatic fat measured by MPM 
has been correlated well with that determined by biochemical analysis. This staining 
free technique has the potential for early diagnosis and rapid detection of liver 
steatosis. 
2.6 Imaging liver physiology and defining liver function  
In the past two decades, the development of MPM has resulted in an explosion 
of mechanistic investigation of liver physiology down to the molecular level. 
Compared to conventional microscopy, MPM has an important advantage of 
intravital imaging, which can enhance our understanding of liver physiology and 
function, and provide new insights into pathogenesis and disease control 
mechanisms. Table 2 shows the characteristics and functions of fluorescent probes 
commonly used in MPM imaging of the liver physiology.   
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2.6.1 Mitochondrial physiology 
        The mitochondrion is a double membrane-bound organelle found in most 
eukaryotic cells. The mitochondrial permeability transition (MPT) is defined as an 
increase in the permeability of the mitochondrial membranes to molecules less than 
1500 Dalton [34]. MPT results from the opening of MPT pores located in the inner 
membrane of the mitochondria under certain pathological conditions such as hepatic 
I/R injury, leading to mitochondrial depolarization and swelling, and cell death 
through apoptosis or necrosis. MPM has been applied to visualize the mitochondrial 
physiology using different fluorescent probes. Propidium iodide (PI) labels the nuclei 
of nonviable cells, and can be used to visualize the overall cell viability [35]. The 
opening of MPT pores could be assessed using calcein acetoxymethyl ester in TPEF 
imaging. Calcein is a fluorescent molecule that cannot be taken up by mitochondria 
after intravenous injection, resulting in the mitochondria appearing as dark voids in 
the hepatocytes in the normal liver [36]. In mice with hepatic I/R injury or bile duct 
ligation, the opening of MPT pores in hepatocytes can be revealed by the 
appearance of calcein fluorescence in the mitochondria matrix space, which are dark 
voids in normal hepatocytes [37, 38]. Rhodamine 123 (Rh123) is another commonly 
used fluorescent dye in TPEF imaging to visualize polarized mitochondria [35]. After 
intravenous injection, Rh123 selectively accumulates in polarized mitochondria of the 
healthy liver, resulting in bright punctate fluorescence of Rh123 in hepatocytes. 
While the liver with hepatic I/R injury [38, 39] or obstructive cholestasis [37] shows 
dim diffuse of Rh123 fluorescence, denoting that many mitochondria did not take up 
Rh123 because of depolarization. Thus, MPM can be employed to investigate the 
drug efficacy. As shown in Fig. 2.6, the effect of NIM811, an MPT inhibitor, was 
evaluated using fluorescent probes of PI and Rh123 to visualize the attenuation of 
mitochondrial depolarization and MPT onset in APAP induced liver injury [40].  
 
18 
 
Table 2.1 Characteristics of major endogenous fluorophores and collagen SHG in normal liver 
Fluorophore Sample 
Excitation 
wavelength* (nm) 
Emission 
wavelength (nm) 
Fluorescence lifetime (ns) Reference 
NAD(P)H Mouse and rat in vivo, 
human ex vivo 
740-800 350 - 490 0.3 - 0.7 (bound), 2.5–3.0 
(free) 
[21, 22, 31, 47] 
FAD Rat in vivo, human ex vivo 800 500 - 620 0.04 - 0.4 (bound), 2.3 - 
2.8 (free) 
[31, 47, 75] 
Elastin Human ex vivo 850 500 - 550 1.96 [25, 43] 
Vitamin A Mouse and rat in vivo 700-830 ~ 500 1.7 – 2.2 [21] 
Porphyrin / 
biliverdin / bilirubin 
Human ex vivo 1230 670 0.4 - 1 [32] 
Collagen SHG Human and rat ex vivo 800 - 1230 1/2 laser 
wavelength 
No lifetime [25, 31, 32, 76] 
*: two-photon excitation 
 
Table 2.2 Characteristics and functions of fluorescent probes commonly used in TPEF imaging of the liver 
Probe Molecular 
weight (g/mol) 
Excitation 
wavelength (nm) 
Emission 
wavelength (nm) 
Function References 
RH 123 380.82 820 500-550 Indicates mitochondrial polarization 
Indicates P-gp function 
[23, 35, 37, 38, 47] 
[42, 44, 67]  
Calcein 622.53 720 500-550 Indicates MPT [38] 
Sodium fluorescein  332.31 920 515-620 Indicates hepatic microcirculation and 
Oatp function 
[42, 62] 
RITC-dextran  70,000 920 573 Labels sinusoids 
Labels abnormal hepatocytes 
[23, 50, 77] 
[51, 67] 
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Table 2.2 - Continued. 
Probe Molecular 
weight (g/mol) 
Excitation 
wavelength (nm) 
Emission 
wavelength (nm) 
Function References 
CFDA 460.39 780 520 Indicates hepatobiliary excretion 
function 
[48, 50, 51, 77] 
TRITC-labeled 
albumin 
443.52 488* 561 Labels sinusoids [57] 
Rhodamine 6G 479,02 530* 556 Labels mitochondria [50] 
TMRM 500.93 548* 574 Indicates mitochondrial polarization [50] 
FITC-dextran 70,000 920 518 Labels sinusoids [50, 54, 67] 
DAPI 277.32 720 461 Labels cell nuclei [78] 
AlexaFluor488 570.48 496* 519 Labels antibody [54, 78] 
PI 668 920 608 Indicates cell viability [35] 
LAURDAN 353.54 800 423-483 Labels liver sinusoidal endothelial 
cells 
[27] 
PE-coupled anti-
PECAM-1 
- 565 or 498* 573 Labels liver sinusoidal endothelial 
cells 
[28] 
Texas red-dextran 70,000 596* 615 Labels macrophages [54] 
PD nanobeads - 545* 575 Labels macrophages [55] 
Carboxylated latex 
particles 
- 580* 605 Labels macrophages [53] 
        *: single-photon excitation, RH 123: Rhodamine 123, RITC-dextran: Rhodamine B isothiocyanate-dextran, CFDA: 
Carboxyfluorescein diacetate, TRITC: tetramethylrhodamine isothiocyanate, TMRM: tetramethylrhodamine methylester, FITC-dextran: 
Fluorescein isothiocyanate-dextran, DAPI: 4',6-diamidino-2-phenylindole, PI: Propidium iodide, LAURDAN: 6-lauroyl-2-
dimethylaminonaphthalene, PE: phycoerythrin, PECAM-1: platelet-endothelial cell adhesion molecule-1, MPT: Mitochondrial permeability 
transition. 
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Figure 2.6 In vivo visualization of mitochondrial depolarization and cell death in mouse 
liver using MPM. (A) NIM811 decreases hepatocellular cell death and/or mitochondrial 
depolarization after both low and high dose APAP. NIM811 (10 mg/kg) was administered 
by gavage 1 h before APAP. Top and bottom rows show intravital MPM and conventional 
histopathological images, respectively. Punctate labeling with Rh123 signifies 
mitochondrial polarization, whereas dim diffuse Rh123 staining denotes mitochondrial 
depolarization (dashed line). Nuclear PI labeling signifies cell death (white arrows). 
Conventional histological images were collected on H&E stained section. Black arrows 
identify necrotic areas. (B and C): Protection by NIM811 against depolarization and cell 
death induced by APAP. Percent area of mitochondrial depolarization is plotted for various 
treatment groups (B). PI-labeled nuclei were also counted (C). N.D., not detectable; 
*P < 0.05. Reproduced with permission [40]. 2016, Oxford University Press. 
2.6.2 Functions of hepatic enzymes and transporters 
Hepatic enzymes and transporters play a significant role in drug metabolism and 
biliary excretion. In most studies, functions of hepatic transporters are evaluated in 
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cultured cell system or isolated perfused liver [41]. However, both methods have obvious 
disadvantages such as limited biological significance in cell lines and indirect analysis of 
transport processes in perfused liver models [42]. Using specific fluorescent probes, MPM 
allows direct measurement of enzyme and transporter functions. Recently, a two-photon 
excited ratiometric fluorescent probe has been developed for sensitive and selective 
detection of CYP1A, one of the most important phase I drug-metabolizing enzymes [34]. 
TPEF imaging can directly assess the functions of hepatic transporters by observing the in 
vivo distribution kinetics of specific fluorescent substrates in the liver [42-44]. For example, 
the functions of biliary canalicular transporter MDR1 (P-glycoprotein, P-gp) and basolateral 
transporter organic anion transporting polypeptide (Oatp) have been evaluated using their 
specific substrates Rh123 [45] and sodium fluorescein [46]. In hepatic I/R injury, the 
uptake and clearance of fluorescein are found to be delayed, probably due to the impaired 
hepatic microcirculation and the dysfunction of efflux transporters [47]. And the impaired P-
gp function can be revealed by the increased fluorescence intensity of Rh123 in the 
hepatocytes with I/R injury compared to sham [7, 44]. 
2.6.3 Hepatobiliary excretory function 
        Bile excretion is part of hepatobiliary function. The liver is responsible for the uptake, 
processing, and excretion of many exogenous or endogenous substances into bile by 
hepatocytes [48]. Carboxyfluorescein diacetate (CFDA) has been used to define the 
hepatobiliary excretory function of healthy mice, mice with APAP-induced liver injury and 
with obstructive cholestasis [48-50]. CFDA is a nonfluorogenic substance and can be 
hydrolyzed by esterase into fluorogenic carboxyfluorescein (CF) after taken up by 
hepatocytes. The kinetics of CF can be determined in hepatocytes and sinusoids 
separately based on its fluorescence intensity. The delayed clearance of CF from 
hepatocytes into bile canaliculi was observed in mice with bile duct ligation. An active 
machinery operating backflow of bile containing CF from hepatocytes into sinusoids was 
found in mice with obstructive cholestasis and APAP-induced liver injury [48, 50, 51].  
In addition, fluorescein has also been used to reflect the hepatobiliary excretory 
function. The uptake and clearance of fluorescein has also been found to be delayed in 
mice with liver steatosis and hepatic I/R injury using TPEF imaging, and confirmed by 
FLIM [47, 52]. Conventional methods for studying the hepatobiliary excretory function 
usually involve biochemical analyses of contents in the bile, liver, blood or urine, while 
MPM enables intravital imaging of fluorescent probes in the liver at the subcellular level. 
This imaging technique can provide further quantitative measures of metabolic and 
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hepatobiliary excretory function, and hence extend the qualitative liver function tests now 
available. 
2.6.4 Cell physiology and migration 
      MPM has been applied to study the cell migration and function in the liver in a variety 
of disease states including HCC, colorectal cancer liver metastases, hepatic I/R injury, 
parasitic infection and liver regeneration. Kupffer cells can be labeled in vivo by 
intravenous injection of red fluorescent carboxylated latex particles [53], 70-kDa Texas 
red-dextran [54] and PD nanobeads (545 marked) [55] due to their macrophage 
phagocytic ability. After labelling, TPEF imaging of the liver reveals that Kupffer cells are 
the main cellular scavenger for circulating particle-associated antigens in homeostasis 
[53]. These cells are the only detectable population of mononuclear phagocytes within 
granulomas induced by Leishmania donovani infection [55]. Kupffer cells do not migrate to 
interact with vessels while infiltrating monocytes interact directly with sinusoids after partial 
hepatectomy [54].  
      Leukocytes are the cells of the immune system that are involved in protecting the body 
against both disease and foreign invaders. These cells can be further divided into five 
main types: neutrophils, eosinophils, basophils, lymphocytes, and monocytes [56]. Green 
fluorescent protein (GFP)-expressing leukocytes were used for MPM imaging in almost all 
the studies, because most leukocytes lack the phagocytic ability and are difficult to be 
labelled using fluorescent dyes [53, 57-59]. The GFP-expressing tumor-infiltrating 
leukocyte adhesion and migration in HCC have been visualized in vivo at the single-cell 
level [57]. Their migration was found in a random manner with frequently changed 
infiltrating directions. In hepatic I/R injury, MPM successfully detected the numbers, 
velocity, and morphology of recruited neutrophils in vivo, and has potential for a wide 
range of applications to investigate the mechanism of I/R injury [58]. 
Recently, MPM has been used to detect the colorectal cancer liver metastases in 
living mice taking its advantages of imaging target organs for a long period at a high 
magnification and in the deep depths from the surface [8, 60]. An animal model of 
colorectal cancer liver metastases was developed by inoculating red fluorescent protein 
(RFP) expressing colorectal cancer cells into the spleens of GFP transgenic mice. As 
shown in Fig. 2.7, the multi-stage tumor metastatic processes have been visualised in this 
mouse model, including tumor cell arrest, tumor cell-platelet interaction, tumor cell-
leukocyte interaction, and metastatic colonization in the liver [8, 61]. These studies are 
good examples of the applications of MPM as a tool for basic investigation. 
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Figure 2.7 Visualisation of the liver metastatic process of colon cancer cells. (A) Colon 
cancer cells arrest in the sinusoid. (B) Tumor cell-platelet interaction. (C) Platelets 
aggregation to the tumor cell. (D) Tumor cell-leukocyte interaction. (E) Tumor cell 
extravasation. (F) Liver metastatic colonization of colon cancer cells. Red color represents 
the colon cancer cells and green color represents the structure of the liver and blood 
vessels. Reproduced with permission [8, 61]. 2014. e-Century Publishing Corporation. 
2012. Koji Tanaka et al. 
2.7 Pharmacokinetic imaging in the liver 
A precise method of understanding and analyzing pharmacokinetic events is to 
directly observe the distribution, metabolism and excretion of diagnostic or therapeutic 
agents in space and over time. MPM provides a powerful tool to spatiotemporally monitor 
the transport of molecules, nanoparticles and biological agents in the liver at the cellular 
level for pharmacokinetic analysis. 
 2.7.1 Molecule imaging 
        The pharmacokinetics of fluorescein and RH123 has been investigated by MPM in rat 
liver [43, 44, 62]. Since MPM allows simultaneous visualization of the organ 
autofluorescence and molecule fluorescence, it is able to determine the levels of 
fluorescent molecules in the sinusoids, hepatocytes and the bile respectively (Fig. 2.8A), 
which enables dividing the liver into subcompartments for pharmacokinetic modelling, as 
seen in Fig. 2.8B. A physiologically based pharmacokinetic (PBPK) model has been 
developed to characterize the kinetics of fluorescein at the single-cell resolution in health 
and diseased liver in vivo [52]. Using the same intravital imaging technique, half-life of 
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Rh123 is calculated by fitting the decay of fluorescence intensity in hepatocytes vs. time 
profile into the exponential equation [44]. 
 
Figure 2.8 Pharmacokinetic imaging of fluorescein in the liver at the cellular level. (A) 
TPEF images of fluorescein in normal rat livers at various time points after bolus injection 
via jugular vein with high magnification (40 ×) (scale bar: 20 μm). The symbol S indicates 
sinusoid, H indicates hepatocyte and B indicates bile duct. Red color represents 
autofluorescence of liver and green color represents fluorescein. (B) Schematic overview 
of compartmental model describing hepatic uptake and elimination kinetics of fluorescein. 
(C and D) Fluorescein concentration-time profiles in the sinusoid and hepatocyte 
compartments. Reproduced with permission [52, 63]. 2015. American Society for 
Pharmacology and Experimental Therapeutics. 2014. John Wiley and Sons. 
 
        Furthermore, FLIM imaging adds the capability of differentiating fluorescent 
molecules from biological tissues based on their fluorescent lifetimes. For example, 
fluorescein and its metabolite fluorescein mono-glucuronide (FG) have an overlapping 
excitation and emission spectra [62], which make them to be hardly distinguished using 
TPEF imaging. However, the fluorescence lifetime of fluorescein and metabolite FG is 
reported to be 3.8 to 4.1 ns and 2.3 ns, respectively [62], which can be differentiated by 
FLIM. The in vivo distribution and metabolism of fluorescein has been studied based on 
the lifetime change in different zonation of rat liver using MPM-FLIM, showing the mean 
lifetimes of fluorescein and FG decease over time after injection [62]. Therefore, the 
combination of MPM and FLIM provides a novel technique for studying real-time 
distribution and metabolism of fluorescent molecules in the liver at a high resolution.  
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        MPM has also been used to real-time evaluate the chemotherapy response on the 
colorectal cancer liver metastases [64]. After administration of 5-fluorouracil or irinotecan, 
tumor cell fragmentation, condensation, swelling and intracellular vacuoles are observed 
under time-series intravital TPEF imaging. A pharmacokinetic/pharmacodynamic model 
could be developed based on these observations. 
2.7.2 Nanoparticle imaging 
        Nanoparticles (NPs) are defined as spherical (or quasispherical) particles with a 
diameter less than 100 nm, but often refer to the range up to 300–500 nm [65]. Since NPs 
have unique physiochemical properties, and have been intensively applied to drug and 
gene delivery, imaging and diagnosis [66], it is important to investigate their 
pharmacokinetics for clinical applications. Although many studies have reported the organ-
level distribution of NPs, very few have addressed their disposition in organs at the cellular 
level [63]. The uptake, distribution and excretion of fluorescent or fluorescent labelled NPs 
can be investigated using TPEF imaging at the single cell resolution [67-70]. Polymeric 
NPs with high bond repetition rate are highly suitable for CARS imaging because the 
CARS signal scales quadratically with the bond concentration [70].  
        The in vivo spatiotemporal disposition of quantum dots (QDs), a typical example of 
long-circulating NPs, has been intensively explored in the liver at a single cell level using 
MPM [63, 71]. The concentration profile of QDs determined from the QD fluorescence 
intensity in sinusoids correlates well with that in the plasma measured by inductively 
coupled plasma mass spectrometry (ICP-MS) [63]. This suggests that MPM may be used 
as a semi-quantitative method to investigate the distribution of fluorescent NPs in living 
organisms, particularly in the initial distribution phase (0.5 to 5 min), when collecting blood 
samples is difficult. Furthermore, the enriched quantified data obtained from MPM imaging, 
especially at early time, allows more sophisticated pharmacokinetic modelling to reveal 
more detail information of NP disposition, while blood sampling and ICP-MS analysis can 
only provide limited data for modelling [63]. As shown in Fig. 2.9, the QD sub-organ 
distribution visualized by TPEF imaging was further confirmed by FLIM imaging based on 
the change of average fluorescence lifetime. Since the fluorescence lifetime of QDs is 
much longer than that of liver cells, the increased fluorescence lifetime in the sinusoid but 
not in hepatocytes after QDs injection confirmed that these negatively charged QDs 
predominantly distributed in the sinusoids [63]. Thus, even if the excitation and emission 
spectrum of a fluorophore overlap with those of the background, it can still be 
distinguished based on different fluorescence lifetimes. 
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Figure 2.9 FLIM images of representative rat liver before, 60 min and 180 min after QD 
bolus injection in emission channel of 350–450 nm (a) and 515–620 nm (c). The 
pseudocolor is based on the average fluorescence lifetime τm (0–2000 ps; blue-green-red). 
(The symbol S indicates sinusoid, H indicates hepatocyte, scale bar: 20 μm). The average 
τ m values at different time points before and after QDs injection are displayed in (b) (in 
channel of 350–450 nm) and (d) (in channel of 515–620 nm). The error bar indicates 
standard deviation (n = 3). Reproduced with permission [63]. 2014. John Wiley and Sons. 
2.7.3 Therapeutic cell imaging 
        Cell therapy has emerged as an evolutionary therapeutic force especially for diseases 
not curable by traditional therapeutics. Mesenchymal stem cell (MSC) is one of the most 
promising and widely used therapeutic cells for many debilitating diseases including liver 
cirrhosis, diabetes, spinal cord injury and myocardial infarction. Recently, a whole body 
PBPK model has been developed based on the organ disposition and cell-tissue 
interactions of GFP-expressing MSCs visualised by MPM [72]. This imaging technique 
opens up a new window for more in-depth investigation about the disposition of molecules, 
nanoparticles and biological agents in the liver and other organs to understand their in vivo 
pharmacokinetics and pharmacodynamics. 
2.8 Summary, limitation and future direction 
A better understanding of the liver anatomy, physiology and pharmacology is 
necessary for developing new diagnostic and therapeutic strategies for liver diseases. This 
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fundamental knowledge can be obtained using various techniques, among which the 
dynamic imaging tools provided by MPM has emerged as a very powerful option to 
researchers. FLIM adds the abilities of MPM to detect environmental changes and 
differentiate fluorophores from biological background according to their lifetimes. As 
summarised in this review, MPM-FLIM has been employed for both ex vivo or in vivo 
imaging of the liver. Intravital MPM preserves physiological conditions more faithfully, but it 
is a demanding technique that requires dedicated personnel. Although most of the 
aforementioned researches are based on animal studies, MPM has already been applied 
to clinical settings to diagnose and assess liver diseases.  
Limited infiltration depth is one of the most significant limitations of MPM. Normally, 
the imaging depth is hundreds of micrometers in MPM. Thus early diseases arising deep 
in the liver tissue are difficult to be diagnosed with this technique. We anticipate that in the 
near future the penetration depths of MPM will be further increased, and new infrared dyes 
will be developed with longer excitation wavelengths that penetrate more deeply due to 
less absorption and scattering. Another limitation is that in vivo MPM imaging of the liver 
can only be achieved after surgical exposure, which grossly impedes its application in 
humans. Miniaturised laser scanning microscope has been developed, which allows 
minimal invasive imaging of the liver through keyhole incisions [73]. Endoscope coupled 
with MPM has also been developed [74], which can image the liver through small surgical 
incision or intrahepatic bile duct as endoscopic retrograde cholangiopancreatography. 
These minimal invasive imaging techniques have provided the possibility of in vivo imaging 
the human liver. Therefore, we anticipate that in the near future MPM will be evaluated 
from bench to bedside, and especially be applied to endoscopic or laparoscopic systems, 
leading to a deep understanding of the anatomy, physiology and pharmacology of the 
human liver. 
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Chapter 3 
Real-time histology in liver disease using 
multiphoton microscopy with fluorescence 
lifetime imaging 
 
 
 
 
 
3.1 Synopsis 
        In this chapter, multiphoton microscopy with fluorescence lifetime imaging was used 
to image live mice livers (normal, with fibrosis, steatosis, hepatocellular carcinoma and 
ischemia-reperfusion injury) for stain-free real-time histology. It is able to simultaneously 
image and quantify the cellular morphology and microenvironment of live livers without 
conventional biopsy or fluorescent dyes.  
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        The article entitled, “Real-time histology in liver disease using multiphoton microscopy 
with fluorescence lifetime imaging” has been published by Biomedical Optics Express, 
2015; 6(3):780-92. The manuscript, figures and tables have been adjusted to fit the overall 
style of the Thesis and incorporated as this chapter. 
3.2 Abstract 
Conventional histology with light microscopy is essential in the diagnosis of most liver 
diseases. Recently, a concept of real-time histology with optical biopsy has been 
advocated. In this chapter, live mice livers (normal, with fibrosis, steatosis, hepatocellular 
carcinoma and ischemia-reperfusion injury) were imaged by MPM-FLIM for stain-free real-
time histology. The acquired MPM-FLIM images were compared with conventional 
histological images. MPM-FLIM imaged subsurface cellular and subcellular 
histopathological hallmarks of live liver in mice models at high resolution. Additional 
information such as distribution of stellate cell associated autofluorescence and 
fluorescence lifetime changes was also gathered by MPM-FLIM simultaneously, which 
cannot be obtained from conventional histology. MPM-FLIM could simultaneously image 
and quantify the cellular morphology and microenvironment of live livers without 
conventional biopsy or fluorescent dyes.  
Key Words: Real-time histology, Liver disease, Multiphoton microscopy, Fluorescence 
lifetime imaging 
 
3.3 Introduction 
        Liver diseases are frequently encountered in clinical practice with high morbidity and 
mortality [1]. Fatty liver disease is a worldwide health problem and potentially progresses 
to steatohepatitis, fibrosis and finally cirrhosis [2]. Primary sclerosing cholangitis is a 
chronic cholestatic liver disease and often develops to liver cirrhosis or even 
cholangiocarcinoma [3]. Hepatocellular carcinoma is the third leading cause of cancer-
related mortality worldwide [4]. Histological examination is essential in the diagnosis of 
most liver diseases. Conventional histology relies on microscopic examination of a 
specimen obtained from biopsy or surgery, which is usually time consuming due to the 
complicated sample preparation procedures including fixation, sectioning and staining. The 
frozen sections of surgical margin are assessed during hepatocellular carcinoma or 
cholangiocarcinoma surgery to achieve a R0 resection (complete resection with 
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microscopic examination of margins showing no tumor cells) [5]. Re-resection and/or re-
anastomosis must be performed if the surgical margin is tumor positive, leading to the 
prolonged operation time. In addition, liver biopsy is often associated with complications 
such as bleeding or bile leak, and can yield false negative results [6]. There is a desperate 
need for a rapid, accurate and safe histological diagnosis method for the successful 
diagnosis and management of liver disease.  
Goetz et al. has recently reported the application of confocal laser endomicroscopy for 
the real-time histological examination of liver disease in both animal models and human [7, 
8]. This technology allows immediate in vivo subsurface microscopic imaging and has 
potential to dynamically monitor pathologic events of liver with high resolution. Compared 
to confocal microscopy, multiphoton microscopy (MPM) has the advantages of less 
photobleaching and photodamage, and has considerably enhanced imaging penetration 
depth due to less scattered multiphoton excitation in samples [9]. Fresh, unprocessed and 
unstained live liver can be imaged in vivo or ex vivo by MPM with excitation in 700 to 800 
nm using intrinsic tissue emissions including two-photon excitation fluorescence (TPEF) 
and second harmonic generation (SHG) [10].  
Fluorescence lifetime imaging (FLIM) coupled with MPM could map the spatial 
distribution of fluorescence lifetime, the average time of an electron stays in the excited 
state before returning to the ground state [11]. It can be used to differentiate endogenous 
fluorophores (e.g. nicotinamide adenine dinucleotide (NADH), collagen, and vitamin A) in 
the liver tissue based on their unique lifetimes. Lifetime changes of these fluorophores 
reflect changes in liver microenvironment, such as pH, protein binding and injury induced 
fibrosis, which are usually associated with disease but cannot be revealed by microscopy 
using fluorescence intensity [9]. 
Liver tissue obtained from biopsy or surgery of various liver diseases, such as liver 
fibrosis [12], hepatitis C virus infection [13], hepatocellular carcinoma and 
cholangiocarcinoma [14] has been examined by MPM. The miniaturized MPM and 
multiphoton probe have been developed recently [15-17], which allows real-time 
histological examination of liver without conventional biopsy for liver disease diagnosis. 
However, there are no systematic studies on MPM features of live normal and diseased 
livers and comparison of those features with conventional histological examination, and 
there is no application of MPM-FLIM in the liver disease diagnosis. Therefore, this study 
aims to establish MPM-FLIM diagnostic features for common liver diseases. Mouse 
models developed to mimic human liver diseases were examined in this study to explore 
the feasibility of real-time histology using this new method. 
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3.4 Materials and Methods 
3.4.1 Chemicals and cells 
Rodent high fat diet (25% fat, 1% cholesterol and 0.5% cholate) was provided by 
Specialty Feeds Pty Ltd (SF12-014, Glen Forrest, Western Australia). Carbon tetrachloride 
(CCl4) was purchased from Sigma Aldrich (St Louis, MO, US). Ilium xylazile and ketamine 
hydrochloride were purchased from Bayer Australia (Pymble NSW, Australia). Hepa 1-6 
cells were obtained from ATCC (Manassas, VA, USA) and maintained in vitro under cell 
culture conditions recommended by ATCC. 
3.4.2 Animal models 
          Male 8-week and 20-week-old FVB/N and 8-week-old BALB/c nude mice were 
purchased from the Animal Resource Centre (Perth, Western Australia). Male 20-week-old 
Mdr2-/- (FVB/N background) mice were purchased from the Jackson Laboratory (Bar 
Harbor, USA). All animal procedures were approved by the Animal Ethics Committee of 
the University of Queensland. 
Healthy mice (six FVB/N and six BALB/c nude, 20g) served as controls and there 
were six mice in each liver disease group. FVB/N mice were induced by feeding mice a 
high fat diet for 14 days before imaging procedure [18]. To study the primary sclerosing 
cholangitis and biliary fibrosis, 20-week-old Mdr2-/- mice were examined. Since the 
homozygous disruption of the Mdr2 gene in mice causes an insufficient excretion of 
phospholipids into the bile, the histological features found in Mdr2-/- mice are similar to 
primary sclerosing cholangitis and biliary fibrosis[19]. Chronic chemical hepatic injury and 
advanced liver fibrosis in BALB/c nude mice was induced by CCl4 intraperitoneally 
injection at a dose of 1 mL/kg, dissolved in olive oil (1:4), twice a week for 5 weeks [20]. 
Hepatocellular carcinoma was induced by intrahepatic implantation of 5 × 106 Hepa1-6 
cells into BALB/c nude mice via open surgical technique and imaging procedures were 
performed after 14 days [21]. Liver ischemia-reperfusion injury was induced by clamping 
the portal vein and hepatic artery supplying the median and left lobes using a 
microvascular clamp. After 45 min of partial ischemia, the clamp was removed to allow 
reperfusion in the liver for 6 h and 12 h.   
3.4.3 MPM-FLIM 
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         MPM was performed using the DermaInspect system (Jen-Lab GmbH, Jena, 
Germany) equipped with an ultrashort (85 fs pulse width) pulsed mode-locked 80-MHz 
titanium sapphire laser (MaiTai, Spectra Physics, Mount View, California). The excitation 
wavelength was set to 740 nm for liver autofluorescence and 800 nm for both SHG and 
autofluorescence signals, with an emission signal range of 350 to 650 nm established 
through the use of a BG39 bandpass filter (BG39, Schott glass color filter, Schott MG, 
Mainz, Germany). Images were recorded with water-immersion 10× or oil-immersion 40× 
objectives (Carl Zeiss, Germany). The laser power was set to 20 or 15 mW for 10× and 
40×magnification imaging, respectively, and the acquisition time for obtaining the images 
was 7.4 s per frame. 
For FLIM, a time-correlated single-photon counting (TCSPC) SPC-830 detector 
(Becker & Hickl, Berlin, Germany) was incorporated into the MPM system. The TCSPC 
module constructs a photon distribution across the x and y coordinates of the scan area. 
Fluorescence emission was spectrally resolved between linearly arranged photon counters 
through the use of dichroic filters in the beam path. The emission light was collected 
spectrally in a channel from 350 to 450 nm at 740-nm excitation for NADH and 800-nm 
excitation for NADH and collagen SHG. 
Mice were anaesthetized initially by an intraperitoneally injection of ketamine 
hydrochloride (80 mg/kg) and xylazine (10 mg/kg). Body temperature was controlled by 
placing mice on a heating pad set to 37°C. A midline laparotomy was performed to expose 
the liver as previously described [22, 23]. MPM-FLIM images of unfixed live livers were 
collected within 30 min after surgical procedures started. Normal saline was used to keep 
the liver moist and attached to the cover glass of ring interfaced to MPM throughout the 
experiment. Twenty-four images from twelve non-overlapping fields were collected per 
mouse (twelve acquired with 740 nm excitation and twelve acquired with 800 nm 
excitation). 
3.4.4 Histopathology 
         Liver specimens from sites of MPM-FLIM imaging were fixed in 4% buffered formalin 
and embedded in paraffin. Serial sections were obtained for Hematoxylin & Eosin (H&E) 
stain to evaluate histopathologic changes and Van Gieson’s stain to evaluate fibrosis. The 
OlyVIA software 2.6 (Olympus, Münster, Germany) was used to visualize and scan the 
slides. 
3.4.5 Data Analysis 
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         Quantitative analysis of the fluorescence intensity images was done using ImageJ 
1.44p (National Institutes of Health, USA). Spatial distribution of stellate cells (positive 
vitamin A-associated autofluorescence) was assessed by densitometric recording of 
positive sites of fluorescence per frame (10× magnification images) within the periportal, 
midzonal and centrilobular regions of liver lobules [24]. The area of stellate cells was 
calculated as percent of the whole liver area of the frame from twelve representative image 
fields. The fluorescent intensity of injured hepatocytes was calculated from dark area in 
twelve representative image of diseased liver, and compared to the same extent in those 
of healthy liver [9]. The nuclear to cytoplasmic ratio was defined as the diameter of the 
nucleus divided by the diameter of the entire cell (along the same line, arbitrary 
orientation) [25]. It was measured along three different arbitrary lines within a cell, and 
tested on eighteen different cells from six representative image fields. 
FLIM images were analyzed using SPCImage software 4.9.7 (Becker & Hickl, Berlin, 
Germany). A bin of two was used in all images when smoothing the decay data prior to 
fitting. The decay curve is a sum of multiple components as each pixel represents an 
overlay of emissions from various fluorophores. In this study, a bi-exponential decay model 
function (F(t) = α1e−t/τ1 + α2e−t/τ2 with α1 + α2 = 1) was used. Since NADH is the only 
fluorophore contributing significantly to the data in a given pixel at 740 nm excitation and 
emission channel from 350 to 450 nm, two lifetimes, τ1 and τ2 could represent the fast and 
slow decay lifetimes of free and protein-bound NADH, respectively. The amplitudes α1 and 
α2 represent the relative concentration fraction of NADH [26]. τm is the weighted average 
lifetime calculated from τ1 and τ2 and their relative amplitudes (τm = α1τ1 + α2τ2). For 
statistical analysis, one-way ANOVA with Dunnett’s test for correction was used to 
compare the data from normal liver against that from each diseased condition. All the 
statistical analysis was done using GraphPad Prism v 6.04 (GraphPad Software Inc., La 
Jolla, California). Results were considered statistically significant with a p-value < 0.05. 
3.5 Results  
3.5.1 Normal liver 
Liver of healthy mice was examined as control. Laser power of 15 to 20 mW was 
found adequate for imaging. The cellular structure of liver could be imaged deep to 250 μm 
below the fibrous capsule of Glisson by MPM. We found that imaging depth of 50 μm was 
the clearest for observing cellular and subcellular morphology (Fig. 3.1A and B). The 
stellate cells were smaller in size but had strong vitamin A-associated autofluorescence 
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(bright dots in Fig. 3.1A and 3.2A), and distributed across the acinus of normal liver 
uniformly. Bright hepatocyte cords were separated from each other by the blood-filled dark 
sinusoids (Fig. 3.2A and B).  
3.5.2 Primary sclerosing cholangitis and biliary fibrosis 
The livers of 20-week-old Mdr2-/- mice showed intercellular fibrosis (Fig. 3.2F and G), 
especially around the medium sized to large bile ducts of the periportal region (Fig. 3.1F 
and G). Injury of hepatocytes was observed as significantly reduced fluorescence (p < 
0.05, Fig. 3.2F). These morphological changes correlated well with histological results 
(Fig. 3.1J and 3.2J), and were similar to the primary sclerosing cholangitis and biliary 
fibrosis. Stellate cells had a normal distribution in 20-week-old Mdr2-/- mice.  
The mean lifetime excited at 740 nm (1555.7 ± 35.5 ps, Fig. 3.1H and 3.2H) did not 
show a statistically significant change compared to those of the control group (p > 0.05, 
Fig. 3.3A), while that excited at 800 nm (980.0 ± 59.3 ps, Fig. 3.1I and 3.2I) significantly 
decreased (p < 0.05, Fig. 3.3B). 
3.5.3 Liver with chronic injury and fibrosis 
The livers of mice receiving CCl4 showed signs of hepatocyte damage, which were 
observed as significantly reduced fluorescence (p < 0.05, Fig. 3.2K). Collagen deposition 
was obvious in the centrilobular region and pseudolobular formation was evident in liver 
(Fig. 3.1K and L). Inhomogeneous distribution of stellate cells was found only in CCl4 
induced fibrotic liver (Fig. 3.1K). The stellate cells reduced in midzonal regions, and 
accumulated in centrilobular region around central veins (p < 0.05). The regional 
redistribution of stellate cells formed bridges between postsinusoidal venules in some liver 
lobules (Fig. 3.1K). The localisation of stellate cells strongly coincided with that of fibrillar 
collagen. Hallmarks of hepatocyte damage, including cellular hyaline inclusions, ballooning 
degeneration and mononuclear cell infiltration, were observed in liver tissue on H&E 
staining. Liver fibrosis was confirmed by Van Gieson’s staining (Fig. 3.1O and 3.2O). 
The mean lifetime excited at 740 nm (1443.1 ± 42.7 ps, Fig. 3.1M and 3.2M) was 
slightly shorter after receiving CCl4 (p > 0.05, Fig. 3.3A), while that excited at 800 nm 
(869.3 ± 132.3 ps, Fig. 3.1N and 3.2N) significantly decreased (p < 0.05, Fig. 3.3B). 
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Figure 3.1 MPM-FLIM and conventional histopathological images of liver in healthy mice, 
Mdr2-/- mice and mice with CCl4 induced liver fibrosis at low magnification (10×) (scale bar: 
80 μm). A, F and K. Fluorescence intensity image recorded at λExc/λEm: 740/350 to 650 nm. 
B, G and L. Fluorescence intensity image recorded at λExc/λEm: 800/350 to 650 nm. C, H and 
M. Pseudocolored τm fluorescence lifetime image (0-2500 ps; blue-green-red) recorded at 
λExc/λEm: 740/350 to 450 nm. D, I and N. Pseudocolored τm fluorescence lifetime image (0-
2500 ps; blue-green-red) recorded at λExc/λEm: 800/350 to 450 nm. E, J and O. Conventional 
histological images were collected on Van Gieson’s stained section. Opened arrows 
indicate collagen, asterisks indicate bile duct, curved arrow indicates bridges formed by 
stellate cells, and filled arrows indicate postsinusoidal venules. 
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Figure 3.2 MPM-FLIM and conventional histopathological images of liver in healthy mice, 
Mdr2-/- mice and mice with CCl4 induced liver fibrosis at high magnification (40×) (scale 
bar: 20 μm). A, F and K. Fluorescence intensity image recorded at λExc/λEm: 740/350 to 650 
nm. B, G and L. Fluorescence intensity image recorded at λExc/λEm: 800/350 to 650 nm. C, 
H and M. Pseudocolored τm fluorescence lifetime image (0-2500 ps; blue-green-red) 
recorded at λExc/λEm: 740/350 to 450 nm. D, I and N. Pseudocolored τm fluorescence 
lifetime image (0-2500 ps; blue-green-red) recorded at λExc/λEm: 800/350 to 450 nm. E, J 
and O. Conventional histological images were collected on Van Gieson’s stained section. 
Curved arrow indicates hepatic sinusoids, red square indicates hepatocytes, red circle 
indicates stellate cells associated autofluorescence, opened arrows indicate collagen, and 
filled arrows indicate cellular necrosis. 
44 
 
3.5.4 Liver with steatosis 
In the liver of mice fed with high fat diet, intracellular micro- and macrovesicular 
steatosis was visualized by MPM. The black intracellular fat vacuole (darker than the 
nuclei) pushed nuclei of hepatocytes aside towards the cell membrane (Fig. 3.4A). The 
cytoplasm of hepatocytes had a sponge-like appearance because of numerous small black 
intracellular fat inclusions. These observations correlated well with conventional histology. 
Intracellular lipid droplets appeared as uncolored circles in liver tissue on H&E staining 
(Fig. 3.4E). No significant fibrosis or inflammatory infiltration was noted. 
The mean lifetimes excited at 740 nm (1460.0 ± 65.7 ps, Fig. 3.4C) and 800 nm 
(1028.7 ± 83.1 ps, Fig. 3.4D) were slightly shorter than those of the control group, but 
were not statistically significant (p > 0.05, Fig. 3.3A and B). 
3.5.5 Liver with hepatocellular carcinoma 
Liver tumor developed in all animals challenged with intrahepatic Hepa1-6 
implantation by day 14. Extensive cell heterogeneity characterized by irregular size and 
shape, increased nuclear to cytoplasmic ratio (p < 0.05, Fig. 3.4F) and intercellular 
collagen (Fig. 3.4G) resembled the histopathological features of poorly differentiated 
hepatocellular carcinoma in human. Few stellate cells were observed. Central necrosis of 
tumor was indicated as areas of significantly reduced fluorescence (p < 0.05, Fig. 3.4F). 
Peri-tumoral hepatocytes showed cellular and nuclear pleomorphisms. The conventional 
histopathological image of fixed H&E (Fig. 3.4J) and Van Gieson’s stained samples 
displayed the similar characteristic. 
The mean lifetimes excited at 740 nm (1221.4 ± 97.1 ps, Fig. 3.4H) and 800 nm 
(471.7 ± 166.5 ps, Fig. 3.4I) decreased significantly in hepatocellular carcinoma compared 
with those in normal liver (p < 0.05, Fig. 3.3A and B). The lifetimes of free and protein-
bound NADH (647.7 ± 20.2 and 2541.7 ± 341.8 ps, respectively), and contribution of 
protein-bound NADH (32.3 ± 4.0%) also significantly decreased (p < 0.05, Fig. 3.3C). 
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Figure 3.3 Mean and 95% confidence interval of lifetime variables excited at 740 and 800 
nm (n = 6 for each group). A. Mean lifetime recorded at λExc/λEm: 740/350 to 450 nm. B. 
Mean lifetime recorded at λExc/λEm: 800/350 to 450 nm. C. The lifetimes of free and protein-
bound NADH, and contribution of protein-bound NADH of normal liver, hepatocellular 
carcinoma and liver with ischemia-reperfusion injury (6 h of reperfusion). Columns, mean 
of twelve representative images; bars, standard deviation of twelve representative images; 
*, statistical significance compared with normal liver. 
3.5.6 Liver with ischemia-reperfusion injury 
Progressive hepatocyte necrosis after ischemia, as indicated by reduced fluorescence 
and cellular vacuolation, was observed during reperfusion from 6 h (p < 0.05, Fig. 3.4K) to 
12 h. The area of necrosis was about 10% at 6 h and progressed to 25% at 12 h of 
reperfusion. Liver injury after ischemia, as indicated by hallmarks of oncotic necrosis 
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including vacuolation and cellular hyaline inclusions, was observed during reperfusion from 
6 h to 12h on H&E staining (Fig. 3.4O). 
The mean lifetimes excited at 740 nm (1344.4 ± 74.9 ps, Fig. 3.4M) and 800 nm 
(1136.3 ± 68.9 ps, Fig. 3.4N) decreased significantly in ischemia-reperfusion injury group 
(6 h of reperfusion) compared with those in normal liver (p < 0.05, Fig. 3.3A and B). The 
lifetimes of free and protein-bound NADH (671.3 ± 29.0 and 2641.3 ± 355.2 ps, 
respectively), and contribution of protein-bound NADH (31 ± 7.9%) also significantly 
decreased (p < 0.05, Fig. 3.3C). 
 
Figure 3.4 MPM-FLIM and conventional histopathological images of liver in mice with fatty 
liver disease, hepatocellular carcinoma and ischemia-reperfusion injury (6 h of reperfusion) 
at high magnification (40×) (scale bar: 20 μm). A, F and K. Fluorescence intensity image 
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recorded at λExc/λEm: 740/350 to 650 nm. B, G and L. Fluorescence intensity image 
recorded at λExc/λEm: 800/350 to 650 nm. C, H and M. Pseudocolored τm fluorescence 
lifetime image (0-2500 ps; blue-green-red) recorded at λExc/λEm: 740/350 to 450 nm. D, I 
and N. Pseudocolored τm fluorescence lifetime image (0-2500 ps; blue-green-red) 
recorded at λExc/λEm: 800/350 to 450 nm. E, J and O. Conventional histological images 
were collected on H&E stained section. Opened arrows indicate intracellular fat vacuole, 
red square indicates hepatocellular carcinoma cells with increased nuclear to cytoplasmic 
ratio, curved arrows indicate collagen, and narrow arrows indicate cellular necrosis. 
3.6 Discussion 
In this study, we performed the first systematic and comprehensive MPM-FLIM live 
imaging of livers (normal, with steatosis, fibrosis, hepatocellular carcinoma, and ischemia-
reperfusion injury) to assess the potential of MPM-FLIM for real-time histology and 
diagnosis of liver diseases.  Histopathological hallmarks of liver diseases including 
steatosis, fibrillar collagen deposition, increased nuclear to cytoplasmic ratio and 
hepatocyte necrosis could be easily characterized from MPM live imaging. Morphological 
changes observed in MPM images were consistent with conventional histological results. 
Additional information of cellular microenvironment such as distribution of stellate cell 
associated autofluorescence and fluorescence lifetime changes could be gathered by 
MPM-FLIM simultaneously, which could not be obtained from conventional histopathology.  
Using channels contained both SHG and autofluorescence signals (800 nm excitation 
and emission signal from 350 to 450 nm), we have differentiated liver fibrosis caused by 
primary sclerosing cholangitis or by chronic hepatic injury. Fibrillar collagen deposited in 
periportal region of liver in Mdr2-/- mice while accumulated in centrilobular region of CCl4 
induced fibrotic liver. These MPM findings are consistent with conventional 
histopathological results in this and previous studies [19, 27]. The SHG makes the specific 
detection of liver fibrosis possible because there is a strong correlation between SHG 
signals and fibrillar collagen (type I and III) in liver, while non-fibrillar collagen (type IV) and 
SHG signals did not correlate [10, 12, 28]. In this study, we found that fluorescence lifetime 
imaging can be used as a fast and accurate real-time quantification of liver fibrosis. Since 
collagen SHG response is effectively instantaneous [26, 29], the mean lifetimes decreased 
in fibrotic liver at excitation of 800 nm (containing both NADH and collagen signals), 
allowing the discrimination from normal liver. Although the decreases of mean lifetime 
excited at 800 nm in fibrotic livers were not as obvious as that of hepatocellular carcinoma 
group, the overall differences were statistically significant. Thus MPM-FLIM would be a 
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powerful tool providing real-time histology which combines morphology and quantitative 
evaluation of liver fibrosis simultaneously. Our future work will be focused on analyzing the 
correlation between the MPM-FLIM results and the Fibrosis-Metavir score, which is 
currently considered as the gold standard in the assessment of liver fibrosis. 
MPM also enables the identification of hepatic stellate cells since these cells store 
80% of vitamin A in the whole body [30], and vitamin A absorbs light with wavelength of 
765 ± 65 nm and could emit strong fluorescence at below 500 nm under MPM [26]. 
Current accepted mechanism for the generation of collagen in liver fibrosis is that 
collagen-producing cells (hepatic stellate cells, portal fibroblasts, and myofibroblasts) are 
activated by fibrogenic cytokines such as TGF-beta1, angiotensin II, and leptin in the 
injured liver [31]. However, little information has been revealed about the activity of these 
cells (such as distribution or proliferation) at the early injury stage. In this study, we 
observed the stellate cell spatial distribution changed in CCl4 induced fibrotic liver directly 
from MPM images, which is consistent with the observation of Vollmar et al. using 
fluorescence microscopy [24]. It is reported that stellate cell accumulation in fibrous septa 
only occurred early after CCl4 exposure (1 to 4 weeks) while significant loss of vitamin A 
storage in liver was found after prolonged periods of CCl4 administration (8 to 12 weeks) 
[24]. We suggest that in pathological conditions such as liver fibrosis caused by chronic 
hepatic injury, the quiescent stellate cells first accumulate in centrilobular region around 
central veins and between postsinusoidal venules at the early injury stage. Then these 
cells change into an activated state, synthesize and secrete fibrillar collagen, and finally 
leading to fibrosis or cirrhosis. While in patients with primary biliary cirrhosis, Cameron et 
al. reported that there was an increase in the total number of lipid vesicles which contain 
mostly vitamin A in stellate cells, but without spatial redistribution or number increase [3]. 
These observations best explain why Mdr2-/- mice had a normal distribution of vitamin A-
associated autofluorescence in this study. Until now, stellate cell numbers and distribution 
have not been used clinically in diagnosis of liver disease. Although other myofibroblast 
populations do make a contribution to liver injury, for example portal myofibroblasts are 
important in cholestasis, only stellate cells could be detected using real-time histology by 
their distinct vitamin A-associated autofluoresce. In this study, we found that the 
morphology and distribution of stellate cells imaged by MPM provide valuable information 
of cellular microenvironment during development of liver fibrosis. This technique might 
serve as an early and differential diagnostic tool for liver disease in clinic in the 
foreseeable future.  
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The nicotinamide moiety of NADH usually absorbs light with wavelength of 340 ± 30 
nm (single-photon excition) and could emit fluorescence at 460 ± 50 nm [32]. For MPM-
FLIM, images obtained in emission channel 350-450 nm under 740 nm excitation mainly 
reflect the fluorescence lifetime of NADH, which is sensitive to the changes in the cellular 
energy metabolism and microvascular oxygen supply [25]. Free NADH is mainly located in 
the cytoplasm, and involved in adenosine triphosphate (ATP) synthesis without oxygen in 
glycolysis, while protein-bound NADH is located in mitochondrial membrane, producing 
ATP in aerobic conditions [9, 33]. The free and protein-bound forms of NADH have similar 
excitation and emission wavelengths, but can be separated by their distinct fluorescence 
lifetimes [34]. In our study, lifetime of free and protein-bound NADH, and contribution of 
protein-bound NADH significantly decreased in hepatocellular carcinoma and liver with 
ischemia-reperfusion injury. Previous studies have found that the lifetime of free and 
protein-bound NADH, and the relative contribution of protein-bound NADH decreased with 
hypoxia [25, 34]. Changes in cellular metabolic pathways and the distribution of NADH 
enzyme binding sites may be responsible for decrease of protein-bound NADH lifetime in 
hypoxia [35]. In carcinoma and ischemia, cellular respiration is shifted to glycolysis, 
producing ATP in anaerobic conditions rather than oxidative phosphorylation for ATP 
production [36, 37]. So the measured decreases in NADH lifetimes and the contribution of 
protein-bound NADH in hepatocellular carcinoma and the liver with ischemia-reperfusion 
injury are consistent with the increased levels of glycolysis in neoplastic and ischemia 
injured cells. We also found the mean lifetimes of NADH in fatty liver disease and CCl4 
induced fibrotic liver were slight shorter than those of the control group, but without 
statistical significance. One possible reason might be the hypoxia in fatty liver or fibrotic 
liver was not as severe as that in hepatocellular carcinoma and liver ischemia-reperfusion 
injury. 
Current limitations of MPM-FLIM include limited infiltration depth. First, cellular and 
subcellular details were clearest at 50 μm below the capsule of Glisson and the maximum 
depth was 250 μm in our study. Thus early diseases arising deep in the liver tissue are 
difficult to be diagnosed with this technique. We anticipate that in the near future MPM-
FLIM will be applicable to endoscopic retrograde cholangiopancreatography (ERCP) to 
image liver lesions from intrahepatic bile duct. The second limitation is that FLIM scan was 
performed using a long-time exposure of 7.4 s. Moving artefacts, such as respiration, 
would decrease the image quality. However, our group found most MPM-FLIM images 
were of excellent quality in rats in vivo [9]. This technique thus bears a great potential to 
permit laparoscopic real-time histology of liver diseases in human. Third, infiltration of 
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inflammatory cells is a vital component of most liver diseases and is scored in all current 
histopathology scoring systems. Fluorescent dyes have to be administrated to provide 
real-time differentiation of inflammatory cells using MPM-FLIM. So until now, this 
technique may not totally replace biopsy.  
In summary, this study demonstrates for the first time that MPM-FLIM is able to 
simultaneously image and quantify the cellular morphology and microenvironment of live 
livers without conventional biopsy or fluorescent dyes. We established a reliable and 
standardized method of real-time histology for liver diseases with optical biopsy and 
compared conventional histopathology, which is considered as the gold standard in the 
clinical assessment of liver disease currently. Although MPM-FLIM may not totally replace 
biopsy now, we anticipate that in the near future this technique will be evaluated from 
bench to bedside, and especially be applied to endoscopic or laparoscopic systems, 
leading to a less invasive real-time histology of liver diseases. 
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Chapter 4 
Dual-mode quantitative imaging of cellular 
oxidative stress for predicting drug response 
in liver injury 
 
 
 
 
4.1 Synopsis 
In this chapter, the fluctuations of cellular oxidative stress during liver injury were 
investigated at the single cell-level resolution. By combining fluorescence intensity imaging 
and fluorescence lifetime imaging, we totally removed any possibility of crosstalk from in 
vivo environmental or instrumental factors, and accurately localised and measured the 
changes in oxidative stress within the liver.   
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        The article entitled, “Two-photon dual imaging platform for in vivo monitoring cellular 
oxidative stress in liver injury” has been published by Scientific Reports, 2017; 7: 45374. 
The manuscript, figures and tables have been adjusted to fit the overall style of the Thesis 
and incorporated as this chapter. 
4.2 Abstract 
Oxidative stress reflects an imbalance between reactive oxygen species (ROS) and 
antioxidants, which has been reported as an early unifying event in the development and 
progression of various diseases and as a direct and mechanistic indicator of treatment 
response. However, highly reactive and short-lived nature of ROS and antioxidant limited 
conventional detection agents, which are influenced by many interfering factors. This 
chapter investigated the fluctuations of cellular oxidative stress during liver injury at the 
single cell-level resolution. By combining fluorescence intensity imaging and fluorescence 
lifetime imaging, we totally remove any possibility of crosstalk from in vivo environmental 
or instrumental factors, and accurately localised and measured the changes in ROS and 
glutathione (GSH) within the liver. This precedes changes in conventional biochemical and 
histological assessments in two distinct experimental murine models of liver injury. The 
ability to monitor real-time cellular oxidative stress with dual-modality imaging has 
significant implications for high-accurate, spatially configured and quantitative assessment 
of metabolic status and drug response. 
Key Words: Oxidative stress, Liver injury, Multiphoton microscopy, Fluorescence lifetime 
imaging 
 
4.3 Introduction 
        Oxidative stress has been reported as an early unifying event in the development and 
progression of various diseases including injury [1, 2], cancer [3], and many inflammatory 
diseases [4]. It reflects an imbalance between the production of reactive oxygen species 
(ROS) and antioxidant defenses, such as glutathione (GSH) [5]. Excessive production of 
ROS damages all components of the cell, including lipids, proteins, and DNA. Some ROS, 
including hydrogen peroxide (H2O2) and hypochlorous acid (HOCl), also act as cellular 
messengers, and can cause disruptions in normal mechanisms of cellular signaling [5]. 
While GSH, the major ROS-scavenging system in cells to reduce ROS stress, can detoxify 
the reactive intermediates and repair the resulting damage. Because ROS and 
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antioxidants have distinct sources of production and are particularly sensitive to upstream 
molecular interventions [6], their detection at the single cell-level resolution could be useful 
for identifying subpopulations of cells with different susceptibility to ROS-induced injury in 
different stages of diseases. Moreover, the oxidative stress endpoints can report early and 
molecular changes due to treatment [7], and have potential to serve as powerful 
biomarkers of drug response. For example, in liver diseases, the primary endpoint of drug 
efficacy is functional recovery of hepatocytes. The current treatment evaluations include 
imaging liver morphology, monitoring blood levels of liver enzymes, bilirubin and markers 
of inflammation, and assessing the signs and symptoms [8]. Yet each of these current 
techniques fails to capture dynamic changes in metabolic state and poorly reflects 
sensitivity to drug efficacy. Cellular and molecular changes of hepatocytes precede 
changes in liver morphology or markers in peripheral blood during treatment. If these 
molecular endpoints can be identified and measured, they would provide powerful 
biomarkers for early-drug response. 
Methods to detect oxidative stress in vivo have encountered technical challenges, 
which prevented implementation of this method for preclinical drug efficacy screening [2, 
9]. A number of GSH and ROS-detection probes have been developed [9-13]. Most of 
them are single-mode intensity-based probes, which can provide quantitative results, but 
may often be influenced by fluid optical properties, endogenous fluorophores, probe 
concentration, and other in vivo environmental or instrumental factors. The fluorescence 
lifetime of probes are independent of these interfering factors, offering accurate and 
ultrasensitive detecting the presence of many components of cell signaling pathways [14]. 
Thus, the combination of fluorescence intensity imaging and fluorescence lifetime imaging 
(FLIM) is an ideal procedure for intracellular oxidative stress investigations with high 
reliability and accuracy. Up to now, however, no such dual-mode probe has been 
developed for in vivo real-time molecular imaging. We have previously synthesized a 
transition-metal complex-based sensing platform for detecting cellular GSH and ROS 
levels in vitro [15-18]. This sensing platform consists of three probes, which exhibit 
favorable photophysical properties including high photostability, selective and quantitative 
response. To further investigate the fluorescence lifetime and two-photon absorption 
behavior of this platform, and advance to monitoring multiple analytes at the single cell-
level resolution in living systems, here we combined fluorescence intensity imaging and 
FLIM to detect oxidative stress in the liver of living mice using this sensing platform. We 
investigated this approach as a tool for monitoring cellular oxidative stress to predict drug 
response in two of the most common types of liver injury: acetaminophen (APAP)-induced 
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liver injury, which accounts for approximately one-half of all acute liver failures in the 
western world today [19], and hepatic ischemia-reperfusion (I/R) injury, which often occurs 
during liver resection and liver transplantation [20]. The drug response predicted by 
cellular oxidative stress was further compared with alanine aminotransferase (ALT) levels 
in blood and histological examination of the liver. This work represents a significant 
advancement in the tools available to study cellular metabolism and predict drug response 
in living systems. 
4.4 Materials and Methods 
4.4.1 Chemicals and cells 
All chemicals were obtained from Sigma-Aldrich (St Louis, MO, USA) unless 
otherwise stated. Bromobimane was purchased from Santa Cruz (Santa Cruz, California, 
USA). PBS was purchased from Invitrogen (Carlsbad, CA, USA). The GSH-detection 
probe (P-GSH), H2O2-detection probe (P-HP) and HOCl-detection probe (P-HA) were 
synthesised according to the literature [15-18]. AML12 cells were obtained from ATCC 
(Manassas, VA, USA) and maintained in vitro under cell culture conditions recommended 
by ATCC. 
4.4.2 In vitro characterisation 
Two-photon absorption spectrum was recorded using DermaInspect system (Jen-Lab 
GmbH, Jena, Germany). The power (15 mW) and laser pulses (80-MHz and 85 fs pulse 
width) were adjusted under the chosen measurement conditions that were kept constant 
throughout this study. Emission spectra were measured on a Perkin-Elmer LS 50B 
fluorescence spectrometer with excitation and emission slits of 10 nm. To determine 
optical responses of probes toward different GSH, H2O2 and HOCl in solution, the 
fluorescence intensities (λex = 850 nm, λem = 515 to 620 nm) of the P-GSH, P-HP and P-
HA (10 μM) in PBS (30 mM, pH = 7.4) were measured 5 min after the addition of GSH, 
H2O2 and HOCl to determine the intensity enhancement. Emission lifetimes were 
measured on an ISS-Chronos multifrequency cross-correlation phase and modulation 
lifetime spectrometer (ISS Inc., Champaign, IL, USA). For examining the applicability of 
probes for detecting cellular GSH and ROS levels using FLIM imaging, 1 × 105 AML12 
cells per well were plated in 12 well plates and incubated for 24 h at 37 °C and 5% CO2. 
To remove the intracellular GSH, cells were incubated in serum free medium containing N-
ethylmaleimide (100 μM) for 1 h at 37 °C in the incubator. Cells were then exposed to 30 
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mM of P-GSH in serum free medium and incubated for 2 h in the same conditions. To 
investigate the photostability of P-GSH, P-HP and P-HA, these probes were incubated in 
PBS or GSH, H2O2 and HOCl under irradiation with a 30 W deuterium lamp (one-photon 
spectrum: 85 to 400 nm) at room temperature. FLIM imaging was performed using 
DermaInspect system (Jen-Lab GmbH, Jena, Germany) equipped with an ultrashort (85 fs 
pulse width) pulsed mode-locked 80-MHz titanium sapphire laser (MaiTai, Spectra 
Physics, Mount View, CA, USA) and a time-correlated single-photon counting (TCSPC) 
SPC-830 detector (Becker & Hickl, Berlin, Germany). The excitation wavelength was set to 
740 nm for autofluorescence and 850 nm for probe signals, with emission signal ranges of 
350 to 450 nm and 515 to 620 nm established respectively through the use of BG39 
bandpass filters (BG39, Schott glass color filter, Schott MG, Mainz, Germany). Images 
were recorded with oil-immersion × 40 objectives (Carl Zeiss, Oberkochen, Germany). The 
laser power was set to 15 mW for× 40 magnification imaging, and the acquisition time for 
obtaining the images was 7.4 seconds per frame. Fluorescence emission was spectrally 
resolved between linearly arranged photon counters through the use of dichroic filters in 
the beam path.  
4.4.3 Animal models 
         Male 8-week-old BALB/c mice were purchased from the Animal Resource Centre 
(Perth, Western Australia). All animal procedures were approved by the Animal Ethics 
Committee of the University of Queensland and were carried out in accordance with 
Australian Code for the Care and Use of Animals for Scientific Purposes 8th edition. For 
APAP-induced liver injury, mice received gavage of 500 mg/kg APAP in 0.9% saline. Liver 
ischemia-reperfusion injury was induced by clamping the portal vein and hepatic artery 
supplying the median and left lobes using a microvascular clamp. After 45 min of partial 
ischemia, the clamp was removed to allow reperfusion in the liver. For drug efficacy 
studies, animals were treated with 150 mg/kg of NAC intravenously 45 min after APAP 
administration [2], and 200 mg/kg of GSH or 150 mg/kg of NAC intravenously 45 min 
before liver ischemia [21]. 
4.4.4 In vivo imaging of GSH and ROS 
         Mice were anaesthetized initially by the intraperitoneal injection of ketamine 
hydrochloride (80 mg/kg) and xylazine (10 mg/kg). Body temperature was controlled by 
placing mice on a heating pad set to 37°C. Intravital imaging of the mouse liver was 
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performed as previously described [22, 23]. Briefly, a midline laparotomy is performed and 
the liver is exposed for imaging. The left lobe of the liver is placed on the metal plate, 
which was slightly raised above the intraperitoneal cavity to minimize pressure on the 
organs underneath. Normal saline was used to keep the liver moist and attached to the 
cover glass throughout the experiment. 50 μM of probe suspended in 0.2 mL PBS was 
injected with a 27 gauge needle into the portal vein. Multiphoton imaging was performed 
using the Lavision Biotec Nikon multiphoton microscopy (LaVision BioTec, Bielefeld, 
Germany) and DermaInspect system (Jen-Lab GmbH, Jena, Germany) equipped with an 
ultrashort (85 fs pulse width) pulsed mode-locked 80-MHz titanium sapphire laser (MaiTai, 
Spectra Physics, Mount View, CA, USA). The excitation wavelength was set to 740 nm for 
organ autofluorescence and 850 nm for probe signals, with emission signal ranges of 350 
to 450 nm and 515 to 620 nm established respectively through the use of BG39 bandpass 
filters (BG39, Schott glass color filter, Schott MG, Mainz, Germany). Images were 
recorded with water-immersion × 10 or oil-immersion × 40 objectives (Carl Zeiss, 
Oberkochen, Germany). The laser power was set to 20 or 15 mW for × 10 or × 40 
magnification imaging, and the acquisition time for obtaining the images was 7.4 seconds 
per frame. For FLIM, a time-correlated single-photon counting (TCSPC) SPC-830 detector 
(Becker & Hickl, Berlin, Germany) was incorporated into the DermaInspect system. The 
TCSPC module constructs a photon distribution across the x and y coordinates of the scan 
area. Fluorescence emission was spectrally resolved between linearly arranged photon 
counters through the use of dichroic filters in the beam path. The emission light was 
collected spectrally in a channel from 515 to 620 nm at 850-nm excitation. Imaging depth 
of 50 to 100 μm below the fibrous capsule of Glisson were chosen and kept constant 
throughout this study. Twenty-four images from twelve non-overlapping fields were 
collected per mouse (n = 5) without the use of randomization and blinding. 
         FLIM images were analysed using SPCImage software 4.9.7 (Becker & Hickl, Berlin, 
Germany). The fluorescence intensity decay curve of each pixel was fitted to a bi-
exponential decay model: F(t) = α1e−t/τ1 + α2e−t/τ2 + C. Two lifetimes, τ1 and τ2 represent the 
fast and slow decay lifetimes; α1 and α2 are the corresponding relative amplitude 
coefficients, where α1 + α2 = 1. C is a constant related to the level of background light 
present and the contribution from all preceding excitation pulses (the ‘offset’-signals). 
When excited by laser pulses with an 80 MHz repetition rate, the slow decay fluorescence 
of the long-lifetime fluorescent probes for hundreds of excitation pulses accumulates and 
forms a quasi-continuous background. This background is significantly larger than the 
background caused by possible incomplete decay of endogenous fluorescence. The 
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‘offset’-signals of reacted probes and the cellular autofluorescence (‘offset’ parameter 
within BH SPCImage determines the baseline of the fluorescence decay curve) were 
adjusted under the chosen measurement conditions that were kept constant throughout 
this study. Since the fluorescence decay of reacted probes is slow compared to the 
measurement time window which is defined by the repetition rate of the laser system, the 
“Incomplete Model” in SPCImage software was used for calculation according to the 
software handbook. 
4.4.5 Single-cell analysis of images 
         The cellular-level image analysis was done using ImageJ 1.44p (National Institutes 
of Health, USA) and Cell Profiler 2.1.0 in Matlab R2015a (The MathWorks Inc.). Grayscale 
FLIM images were imported and cell pixels were smoothed. The resulting round objects 
between 30 and 70 pixels in diameter were segmented and saved as the cell within the 
image. An Otsu Global threshold was used to improve propagation and prevent 
propagation into background pixels. Then corresponding fluorescence intensity images 
were imported. Subpopulation analysis was performed by generating histograms of all cell 
values from fluorescence intensity images of positive cells identified by FLIM images. Each 
histogram was fitted to 1 and 2 component Gaussian curves. The lowest Akaike 
information criterion (AIC) signified the best fitting probability density function for the 
histogram. Probability density functions were normalized to have an area under the curve 
equal to 1. The OSI was calculated as the ratio of the mean intensity of cellular ROS to the 
mean intensity of cellular GSH. 
4.4.6 Tissue collection and plasma biochemical measurements 
         Mouse blood (0.2 mL) was collected in lithium heparin tubes from the inferior vena 
cava using a 30 gauge needle. At the end of the experiment, the liver, kidney and spleen 
were excised, and portions were immersed into 10% buffered formalin for histological 
assessment. Plasma concentration of alanine aminotransferase (ALT) was measured 
using a Hitachi 747 analyzer (Hitachi Ltd., Tokyo, Japan). 
4.4.7 Histology 
         Organ specimens were fixed in 4% buffered formalin and embedded in paraffin. 
Sections were obtained for Hematoxylin & Eosin (H&E) stain to evaluate histopathologic 
features. The OlyVIA software 2.6 (Olympus, Münster, Germany) was used to visualise 
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and scan the slides. Bromobimane was used for labelling GSH in liver sections on slides 
according to the manufacturer instructions. 
4.4.8 Statistical tests 
         Student’s t test with a Bonferroni correction was used to compare the data between 
groups. All the statistical analysis was done using GraphPad Prism v 6.04 (GraphPad 
Software Inc., La Jolla, California). Results were considered statistically significant with a 
p-value < 0.05. 
 
4.5 Results  
4.5.1 Sensing mechanism of the two-photon dual imaging probes 
This two-photon sensing platform consists of three probes (Fig. 4.1A), which combine 
a tris(2,2’-bipyridine)Ru(II) complex as the turn-on fluorescent unit, with the specific 
responsive group for GSH, H2O2 or HOCl, which also serves as an electron acceptor. 
Excitation of the tris(2,2’-bipyridine)Ru(II) complex leads to the triplet state of metal-to-
ligand charge transfer (3MLCT), and by this process, the metal electrons are transferred to 
the bipyridine ligands in an emissive state. As shown in Fig. 4.1B, when this ligand is 
conjugated to a strong electron acceptor, such as phenyl-2,4dinitrobenzenesulfonate in the 
P-GSH, the electron transfer destination will be diverted from 2,2’-bipyridine to phenyl-
DNBSO. Thus, the 3MLCT is corrupted and the fluorescence and lifetime of the Ru(II) 
complex are quenched by an intramolecular photo-induced electron transfer process 
(PET). While the reaction with GSH, H2O2 or HOCl can specifically trigger the quantitative 
cleavage of the electron acceptor group, and the PET process is eliminated, then the 
fluorescence of the ruthenium complex can be turned on.  
62 
 
 
Figure 4.1 Design of two-photon sensing platform for imaging of oxidative stress. (A) 
Illustration of the sensing mechanism. This sensing platform consists of two parts: a 
ruthenium complex as the turn-on fluorescent unit, and a responsive group as the GSH, H2O2 
or HOCl reaction moiety. (B) Response reaction of P-GSH, P-HP and P-HA toward GSH, 
H2O2 or HOCl, respectively. The probes are non-fluorescent due to the effective photo-
induced electron transfer process (PET). In the presence of GSH, H2O2 or HOCl, the 
responsive group can be quantitatively cleaved, and the reaction ruthenium complex will 
become highly fluorescent. The protonation state of P-HP depends on the organelle pH 
values. The counter-ions are sodium and potassium in biological conditions. 
4.5.2 In vitro characterization of the two-photon dual imaging probes 
We have previously reported that the ruthenium complex has a broad single-photon 
absorption spectrum from 350 to 550 nm [15-18]. For in vivo application of deep-tissue 
imaging, we first evaluated the two-photon absorption spectrum of these two-photon dual 
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imaging probes. Fig. 4.2A shows the two-photon absorption spectrum of P-GSH with a 
peak at 850 nm, and its emission spectrum with a peak at 612 nm. To determine the 
fluorescence intensity of P-GSH in response to GSH, we added GSH in a stepwise 
manner and measured the fluorescence signal in an emission channel of 515-620 nm at a 
two-photon excitation wavelength of 850 nm. The dose-dependent intensity enhancement 
of P-GSH showed good linear relationships in the concentration range from 0 to 10 μM of 
GSH, and the maximum intensity was at the concentration of 20 μM (Fig. 4.2B). The P-HP 
and P-HA have similar excitation and emission spectra to that of P-GSH (Supplementary 
Fig. 4.1A and B). Good linear correlations can be obtained in the concentration range from 
0 to 50 μM of H2O2 and 0 to 40 μM of HOCl (Supplementary Fig. 4.1C and D). Because 
of the differences in specific responsive groups and PET process, the P-GSH, P-HP and 
P-HA have different sensitivity for detection of GSH, H2O2 and HOCl. Metal complex-
based probes have been reported to be particularly suitable for FLIM imaging because 
their fluorescence lifetime (typically more than 50 ns) is much longer than those of tissue 
(2-3 ns) and most organic dyes (1-5 ns) [24]. So we further measured the fluorescence 
lifetime of P-GSH in PBS. The P-GSH has a characteristic 38-fold increase of emission 
lifetime from 6 to 225 ns in the presence of GSH (Fig. 2C and D). P-HP and P-HA also 
have over 20-fold increase of emission lifetime from 5.5 and 4.3 ns to 146 and 90.5 ns, 
respectively. The optical characteristics of P-GSH, P-HP and P-HA are summarised in 
Supplementary Table 4.1. 
We have previously reported the specificity and in vitro cellular uptake properties of 
these probes [15-18]. To further examine their applicability for detecting cellular GSH and 
ROS levels using FLIM, probes (30 μM) were incubated with a mouse hepatocyte cell line 
(AML12) in culture media for 2 h. Fig. 4.2E displays the spatial distribution of the 
fluorescence lifetime signal of P-GSH in the AML12 cells in two emission channels. 
According to our previous work, long-lifetime fluorescent probes can be differentiated in 
vivo using the slow decay lifetime τ2, rather than the fast decay lifetime τ1. Thus, in this 
study, the pseudo-color was based on the slow decay lifetime (τ2) of individual pixel. In the 
350-450 nm spectral channel (left), the fluorescence signal mainly comes from 
nicotinamide adenine dinucleotide phosphate (NAD(P)H), which is a major endogenous 
fluorophore in cells. The spectral channel of 515-620 nm (right) captured the fluorescence 
signal of P-GSH, as well as aufluorescence signal from flavin adenine dinucleotide (FAD) 
in cells. Characteristic longer slow decay lifetimes (> 100 ns) could be detected within the 
cells after P-GSH administration in the 515-620 nm spectral channel. While no such long 
lifetime was observed after cells incubated with a thiol scavenger, N-ethylmaleimide 
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(NEM), to remove the endogenous GSH. Because reacted probe has much longer lifetime 
compared to unreacted probe and FAD, we believe the significant increase of τ2 with the 
cells after probe administration is due to the reaction of probe and their specific substrate. 
These results confirm that the cellular lifetime change is attributed to the reaction of P-
GSH with endogenous intracellular GSH. 
To investigate the photostability of P-GSH, P-HP and P-HA for in vivo imaging, we 
next incubated probes in PBS under irradiation with a deuterium lamp at room 
temperature, whilst fluorescence intensity and fluorescence lifetime was assessed over 
time (Supplementary Fig. 4.2). There was no significant change in the fluorescence 
intensity (Supplementary Fig. 2) or fluorescence lifetime during the 2 hour irradiation. 
Thus, our dual imaging probes exhibit characteristic long emission lifetime with two-photon 
excitation and high photostability required for detecting GSH or ROS levels in 
pathophysiological conditions in vivo. 
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Figure 4.2 Spectral characterization of P-GSH in vitro. (A) Two-photon absorption and 
emission spectra of P-GSH reacted with 10 μM of GSH in PBS buffer. (B) Fluorescence 
response of P-GSH (10 μM) to varying concentrations of GSH. (C) Emission decay of P-
GSH in PBS buffer. (D) Emission decay of P-GSH in PBS buffer with GSH (20 μM). (E) 
FLIM images of representative P-GSH loaded AML12 cells with (lower row) or without 
(upper row) NEM treatment. The autofluorescence of NAD(P)H was collected at λExc/λEm: 
740/350 to 450 nm. The fluorescence signal for probes and FAD was collected at λExc/λEm: 
850/515 to 620 nm. Values are the mean for n = 5 replicates. 
4.5.3 Imaging of cellular oxidative stress in APAP-induced liver injury 
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The mechanism of APAP-induced liver injury is well established. An overdose of 
APAP can lead to oxidative stress through the overproduction of ROS (mainly H2O2). This 
results in the consumption of key cellular antioxidants, such as GSH, initiating a signaling 
cascade that results in necrotic cell death. GSH and the GSH precursor N-acetylcysteine 
(NAC) can scavenge the reactive metabolites, and have been used to treat patients with 
APAP overdose [25, 26]. Thus APAP-induced liver injury serves as an ideal model of 
investigating the potential of cellular oxidative stress for early prediction of treatment 
response in a clinically relevant model. 
We anesthetized the mice and exposed the liver at 60 min after APAP administration. 
Fluorescence intensity imaging and FLIM were acquired at 15 min after injection of 50 μM 
of P-GSH or P-HP into the portal vein (Supplementary Fig. 4.3). As shown in Fig. 3A, 
signals induced by the probes response to GSH in cells were clearly observed using both 
fluorescence intensity imaging and FLIM methods. A significant increase in P-GSH 
fluorescence was observed in some hepatocytes (circled in white). Further analysis of 
FLIM data reveals a significant increase (> 100 ns) in the slow decay lifetime of this area 
after injection of P-GSH, which reacting with GSH is responsible for the change of lifetime 
(Fig. 3B and C). Some false-positive hepatocytes determined by fluorescence intensity 
imaging (circled in yellow in Fig. 4.3A) were found with shorter fluorescence lifetime using 
FLIM, which removes all the possibilities of crosstalk from in vivo environmental or 
instrumental factors. There was no significant decrease of probe signals up to 2 hours 
after injection. We compared P-GSH to bromobimane, a fluorescent heterocyclic 
compound commonly used for GSH sensing [27, 28]. The fluorescence signal produced by 
bromobimane cannot be differentiated from the liver autofluorescence in vivo after 
intraportal injection. Comparable fluorescence intensity imaging of GSH can only be 
obtained from liver sections treated with bromobimane (Supplementary Fig. 4.4). The 
percentage of GSH-positive hepatocytes has no significant difference between this 
detection method and FLIM (p > 0.05). Thus these ex vivo imaging results using 
bromobimane confirmed the in vivo results using P-GSH. While the photochemical 
characteristics of bromobimane based imaging restrict its utility to ex vivo tissue in contrast 
to in vivo P-GSH imaging of the GSH generation in the liver injury.  
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Figure 4.3 Dual-mode in vivo imaging of GSH in hepatocytes of mice after APAP 
administration. (A) Representative fluorescence intensity and FLIM images of mouse liver 
before and 15 min after probes injection. All images were recorded at λExc/λEm: 850/515 to 
620 nm. Scale bar: 20 μm. (B) Sketch to illustrate the parameters of the fit procedure of 
the fluorescence decay curve. Two lifetimes, τ1 and τ2 represent the fast and slow decay 
lifetimes. The slow decaying fluorescence accumulates on repeated laser pulsing to create 
enhanced background signal, defined as ‘offset’. (C) Fluorescence decay fit curves of 
representative area (circled in white) before (Blue) and after (Red) P-GSH injection. 
 
Having quantified the cellular oxidative stress response following APAP-induced liver 
injury, we next evaluated the therapeutic context. As shown in Supplementary Fig. 4.5, 
zonal GSH changes in the liver during NAC treatment were identified in fluorescence 
intensity images and FLIM at low magnification. Representative dual-mode images of GSH 
and H2O2 at high magnification (Fig. 4.4A and B) demonstrate the high-resolution 
capability of this technique, which allows single-cell analysis (Supplementary Fig. 4.6) 
and population modeling for quantification of cellular subpopulations with varying oxidative 
stress. Calculated from FLIM images, we found that NAC treatment significantly increased 
the percentage of GSH-positive hepatocytes, and decreased that of H2O2-positive 
hepatocytes, compared with the untreated (p < 0.05, Fig. 4.4C and E). Population density 
modeling of cellular distributions of the GSH intensity calculated from fluorescence 
intensity images revealed two populations of GSH-positive hepatocytes at 75 min after 
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APAP administration, both lower than the mean intensity of the controls (Fig. 4.4D). The 
NAC treated group has a single population with higher fluorescence intensity maxima at 30 
min after NAC administration. This heterogeneity of cellular GSH level was not seen after 
NAC treatment, suggesting that the APAP sensitive cell subpopulation responses to NAC 
treatment. The comparison of H2O2 intensity determined on a per cell basis showed similar 
distributions between groups as to GSH intensity (Fig. 4.4F).  
A composite endpoint, the optical oxidative stress index (OSI), was computed as the 
ratio of the mean intensity of cellular ROS to the mean intensity of cellular GSH [29]. After 
30 min of NAC treatment, the optical OSI was significantly reduced compared with the 
untreated (p < 0.05, Fig. 4.5A). By 2 hours, the optical OSI further decreased in the 
treatment group (p < 0.05). The imaging results were compared with conventional 
biochemical and histological assessment. As shown in Fig. 4.5B, a significant reduction in 
plasma alanine aminotransferase (ALT) levels associated with NAC treatment was first 
detected 3 hours after therapy. Furthermore, an increase beyond control levels was not 
detected until 2 hour after delivery of APAP. Histological changes were not apparent 30 
min after NAC treatment (Fig. 4.5C). Remediation of APAP-induced hepatocellular 
necrosis was observed in hematoxylin and eosin (H&E) stained sections of liver tissue 3 
hours after NAC treatment. The optical OSI changes therefore precede the conventional 
measures such as plasma liver enzyme levels or histological features of liver injury. In 
addition, no obvious necrosis and abnormity were observed in the sections of liver, kidney 
and spleen tissue from the control group (Supplementary Fig. 4.7), suggesting that the 
two-photon dual imaging probes have no distinct toxicity. Altogether, these results confirm 
the utility of this sensing platform for monitoring cellular oxidative stress to predict drug 
response to APAP-induced liver injury in vivo. 
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Figure 4.4 Dual-mode quantitative imaging of the change of oxidative stress in 
hepatocytes responses to NAC treatment against APAP induced liver injury. (A and B) 
Representative fluorescence intensity and FLIM images of cellular GSH or H2O2 of the 
control, APAP, APAP + NAC groups at 30 min after NAC treatment (75 min after APAP 
administration). All images were recorded at λExc/λEm: 850/515 to 620 nm. Scale bar: 20 
μm. (C and E) The percentages of GSH or H2O2-positive hepatocytes of the control, 
APAP, APAP + NAC groups. (D and F) Population density modeling of the mean GSH or 
H2O2 intensity per cell in control APAP, APAP + NAC groups. Values are the mean ± s.d. 
for n = 5 mice; * p < 0.05, compared with APAP groups; # p < 0.05, compared with control 
group. 
70 
 
 
 
Figure 4.5 Optical oxidative stress index (OSI) of the liver detects response to NAC 
treatment against APAP induced liver injury. (A) Optical OSI of the liver at 30 min and 2 
hours after NAC treatment (75 and 165 min after APAP administration). (B) Concentration-
time profile of ALT levels in peripheral blood of the APAP and APAP + NAC groups. (C) 
Representative histology (H&E staining) of the liver of the control, APAP, APAP + NAC 
groups at 30 min and 3 hours after NAC treatment (75 and 225 min after APAP 
administration). Arrows indicate cellular necrosis. Values are the mean ± s.d. for n = 5 
mice; * p < 0.05, compared with untreated groups; # p < 0.05, compared with control 
group. 
4.5.4 Imaging of cellular oxidative stress in hepatic ischemia-reperfusion injury 
It is well documented that during hepatic I/R injury, ROS (mainly HOCl) are generated 
by neutrophils and diffuse into hepatocytes, causing oxidant stress-mediated injury [30]. 
This pathway can be inhibited by administration of GSH or NAC [31]. Therefore, we used a 
mouse hepatic I/R injury as an independent model to test the potential of evaluating 
cellular oxidative stress for early prediction of treatment response. At 30 min after 
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reperfusion, we observed reductions in the percentage of HOCl-positive hepatocytes and 
mean HOCl intensity in both GSH and NAC treated groups using P-HA (Fig. 4.6A, B and 
C), indicating successful remediation of cellular ROS. There were differences in treatment 
response between GSH and NAC. Consistent with reports that GSH is inferior to NAC as 
an antidote to hepatic I/R injury [31], GSH treatment resulted in production of higher HOCl 
level compared to the NAC treated group though still lower than the untreated group (p < 
0.05, Fig. 4.6B and C). Additionally, GSH and NAC increased cellular GSH to the same 
extent (Supplementary Fig. 4.8).  
The optical OSI significantly decreased in both GSH and NAC treated groups 
compared with the untreated group from 30 min after reperfusion (p < 0.05, Fig. 4.6D). 
The difference in optical OSI between GSH and NAC treated groups was observed at 2 
hours after reperfusion (p < 0.05). However, no difference in ALT levels in peripheral blood 
was detected between the treatment groups within 4 hours after reperfusion (Fig. 4.6E). 
As shown in Fig. 4.6F, the drug response predicted by dual-mode quantitative imaging 
was consistent with reduced hepatocyte necrosis observed in H&E stained sections of liver 
tissue. The optical OSI changes therefore precede the conventional measures such as 
plasma liver enzyme levels or histological features of hepatic I/R injury. These results fully 
characterize optical OSI and show its potential for monitoring early-drug response in vivo 
at the single-cell level. 
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Figure 4.6 Quantitative in vivo detection of different responses to GSH and NAC treatment 
against hepatic I/R injury. (A) Representative fluorescence intensity and FLIM images of 
cellular HOCl of the control, I/R, I/R + GSH, and I/R + NAC groups at 30 min after 
reperfusion. All images were recorded at λExc/λEm: 850/515 to 620 nm. Scale bar: 20 μm. 
(B) The percentages of HOCl-positive hepatocytes in all groups. (C) Population density 
modeling of the mean HOCl intensity per cell in the I/R, I/R + GSH, and I/R + NAC groups. 
(D) Optical OSI of the liver at 30 min and 2 hours after reperfusion. (E) Concentration-time 
profile of ALT levels in peripheral blood of the I/R, I/R + GSH, and I/R + NAC groups. (F) 
Representative histology (H&E staining) of the liver of all groups at 4 hours after 
reperfusion. Arrows indicate cellular necrosis. Values are the mean ± s.d. for n = 5 mice; * 
p < 0.05, compared with untreated groups; # p < 0.05, compared with I/R + GSH group. 
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4.6 Discussion 
Oxidative stress contributes to a diverse array of physiological and pathological 
events in living organisms, but there is an insufficient understanding of how its cellular 
fluxes initiate signaling cascades in living animals in stages of health, aging, and disease 
[32]. Whereas a growing number of chemical tools have been developed to probe redox 
biology, technologies that can monitor fluctuations in cellular redox environment in living 
animals remain limited. We showed that our transition-metal complex-based sensing 
platform is capable of simultaneous two-photon fluorescence intensity imaging and FLIM, 
enabling accurate in vivo detection of ROS and GSH at the single cell-level resolution. 
Moreover, the imaging results correlate well with conventional markers of liver injury such 
as liver enzyme levels and histology, which validate the optical OSI as a prodromal 
imaging biomarker for prediction and evaluation of drug efficacy.  
Although molecular probes have been widely used in biomedical imaging, most of 
these studies exclusively involve steady-state emission where changes in intensity or 
emission energy of the probes are used as the imaging signal [24]. Metal complex-based 
probes are particularly suitable for lifetime-based imaging, as they emit from long-lived, 
triplet-based excited states that are usually efficiently populated through the heavy-atom 
effect. For example, many metal complex-based probes can cross the membrane and 
accumulate in the mitochondria to detect metabolic status in mitochondria of cells. 
Ruthenium-based probes have been developed for lifetime-based imaging of the cellular 
DNA, RNA and oxygen levels [24, 33]. Furthermore, metal complexes often possess high 
two-photon absorption cross-sections, making them particularly compatible with two-
photon based lifetime microscopy techniques [34]. In particular, the π-conjugated ligands 
of our metal complex-based probes endow them with two-photon absorption property for in 
vivo deep-tissue imaging. Moreover, the rapid sensing kinetics and large dynamic range of 
sensitivity allow our metal complex-based probes to detect nanomolar to micromolar levels 
of ROS and GSH in near–real time. This permits sensitive monitoring of cellular oxidative 
stress levels as a mediator of liver injury. This sensing platform has advantages over 
small-molecule fluorescent-based probes for in vivo ROS or GSH imaging reported to 
date. Conventional emission-based detection methods are influenced by probe 
concentration and the biomolecular microenvironment [10, 35, 36], or have only been 
employed under one-photon model [9, 37]. We found metal complex-based probes can 
uniquely overcome current limitations to improve detection accuracy in quantitative 
visualization of oxidative stress by FLIM. In addition, since these probes do not have 
significant systemic toxicity in animals, they may also be applied to study the etiology and 
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pathophysiology of diseases involving oxidative stress. It is also worth mentioning that the 
chief limitation of these probes is their irreversibility. They cannot report on decreases of 
GSH, H2O2 and HOCl concentrations. Once all reacted, they will not report any more 
changes of the actual GSH, H2O2 and HOCl concentrations. Therefore, reversible probes 
such as conjugated polymer based phosphorescent nanoparticles will be highly needed in 
the future for in vivo quantitative measurement. Another limitation of this study is the short 
observation time window of FLIM (12.5 ns) in our multiphoton microscopy (LaVision and 
DermaInspect). Although we do have detected significant increases in the slow decay 
lifetime within the cells after probe administration, phosphorescence lifetime detection is a 
much better suitable technique to accurately determine the long fluorescence lifetime of 
the probes. 
 Current methods of evaluation of drug response are generally based on organ 
morphology, histological characteristics, and biomarkers in peripheral blood. Molecular 
changes induced by treatment precede changes in morphology or these biomarkers, and 
may provide proximal endpoints of drug response [38]. The optical OSI from dual-mode 
images using metal complex-based probes captures these drug-induced changes in GSH 
and ROS, which have been hypothesized to correlate closely with treatment outcomes [6, 
39]. Our study introduce the concept of molecular imaging as a tool to study drug response 
in vivo, and is the first to correlate optical OSI with a standard assay of drug response in 
liver injury. The data presented here support the use of optical OSI as an effective imaging 
biomarker for evaluation of drug response, as cellular H2O2, HOCl and GSH levels change 
at an early stage after liver injury, and precede even histological signs of liver tissue and 
changes of liver enzymes in peripheral blood. Beyond the study of liver injury, optical OSI 
may also have utility predicting drug response in other systems. For example, in 
neurodegenerative diseases, ROS have been implicated as the initiators of protein 
misfolding and the downstream inducers of cell death [40]. ROS also have an important 
role in inflammatory diseases, acting as effectors and signaling molecules in both the 
innate and adaptive immune response [7]. ROS levels change rapidly during anti-cancer 
therapy. High levels of ROS generated by chemotherapeutic agents for liver cancer, such 
as doxorubicin, platinum drugs and 5-fluorouracil, can induce cancer cell death [41, 42]. 
Thus, detection of oxidative stress in real time and with high spatial and temporal 
resolution using metal complex-based probes may help uncover mechanisms of ROS 
production and action in a broad range of diseases and contribute to the development of 
new therapeutics. 
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High-resolution image analysis revealed initial heterogeneous GSH and ROS levels 
among hepatocytes after APAP-induced injury (Fig. 4D and F). The cellular details of the 
liver can be imaged deep to 250 μm below the fibrous capsule of Glisson using 
multiphoton microscopy. According to our previous study, imaging depth of 50 to 100 μm 
was the clearest for observing cellular and subcellular morphology in the liver. 
Hepatocytes around the central vein (Zone 3) are more sensitive to APAP-induced injury 
than those around the portal vein (Zone 1) [43]. Consistent with this, our data suggest that 
there exist two intrinsic subpopulations of hepatocytes with differential tolerance to APAP 
toxicity. This heterogeneity of cellular GSH and ROS levels was not seen after NAC 
treatment, suggesting that NAC is protective to this APAP sensitive subpopulation. The 
ability to detect disease severity at a cellular level before treatment may provide leads for 
identification of drugs that target such susceptible subpopulations before they are selected 
by the primary therapy.  
In conclusion, in this proof-of-concept study using a two-photon sensing platform, we 
present the first dual-mode quantitative imaging of cellular oxidative stress in vivo. The 
high resolution and high accuracy of imaging allows subpopulation analysis for 
identification of heterogeneous disease severity among cell populations and assessment 
of drug response. We demonstrate that optical OSI can be used as an early and sensitive 
indicator of metabolic response to treatment in two distinct models of liver injury. 
Altogether, these results suggest that two-photon dual imaging probes are a powerful tool 
to monitor the production and action of cellular oxidative stress in a broad range of 
diseases and inform the rational modification of treatment decisions accordingly. 
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Supporting Information 
 
Supplementary Figures 
 
Fig. S4.1. Spectral characterization of P-HP and P-HA in vitro. (A, B) Two-photon absorption 
and emission spectra of P-HP and P-HA reacted with 50 μM of H2O2 and 40 μM of HOCl in 
PBS buffer, respectively. (C, D) Fluorescence response of P-HP and P-HA (10 μM) to 
varying concentrations of H2O2 and HOCl, respectively. Values are the mean for n = 5 
replicates. 
 
Fig. S4.2. Signal stability of P-GSH, P-HP and P-HA in vitro. Probes were incubated in 
PBS under the irradiation with a 30 W deuterium lamp at room temperature, and 
fluorescence was assessed over time. There was no significant change in the 
fluorescence intensity during the 4 hours of irradiation. Values are the mean for n = 5 
replicates. 
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Fig. S4.3. In vivo imaging of cellular ROS and GSH in mouse liver. (a) Top and side views 
of the metal plate for imaging the liver using multiphoton microscopy. (b) A midline 
laparotomy is performed and the liver is exposed for imaging. (c) For in vivo imaging, the 
left lobe of the liver is placed on the metal plate, which attaches to an adjustable stand that 
could be elevated or lowered as required. (d) Schema for dual-mode imaging of cellular 
oxidative stress using metal complex-based probes. 
 
Fig. S4.4. Representative fluorescence intensity images of liver sections stained by 
Bromobimane (top), with corresponding image enlargements (bottom). The change of 
GSH intensity was observed after NAC treatment, correlating well with that in vivo 
detected using our metal complex-based probes. 
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Fig. S4.5. Dual-mode quantitative imaging of the change of GSH in hepatocytes 
responses to NAC treatment against APAP induced liver injury at low magnification (10×). 
Hepatocytes around the portal vein (circled area) are less sensitive to APAP-induced GSH 
decrease. All images were recorded at λExc/λEm: 850/515 to 620 nm. Asterisks indicate 
portal vein. Scale bar: 20 μm. 
 
 
Fig. S4.6. Single-cell analysis of high-resolution fluorescence intensity images. 
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Fig. S4.7. Representative histology (H&E staining) of major organs of mice after injection 
of 50 μM of probes. No obvious necrosis and abnormity were observed in the sections of 
liver, kidney and spleen by histological examination. Scale bar: 80 μm. 
 
 
Fig. S4.8. The percentages of GSH-positive hepatocytes in all groups. Values are the 
mean ± s.d. for n = 5 mice; * p < 0.05, compared with untreated groups. 
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Supplementary Tables 
Table S4.1. Optical characteristics of P-GSH, P-HP and P-HA 
 
Probe Two-photon absorption 
peak (nm) 
Emission peak 
(nm) 
fluorescence lifetime 
(ns) 
P-
GSH 
850 612 225 
P-HP 850 645 146 
P-HA 850 600 90.5 
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Chapter 5 
 
Visualisation and modelling of the in vivo 
fate of mesenchymal stem cells for the 
treatment of liver cirrhosis 
 
 
 
 
 
5.1 Synopsis 
In this chapter, the spatiotemporal disposition of therapeutic mesenchymal stem cells 
was directly visualised using intravital multiphoton microscopy. A physiologically based 
kinetic model was then developed to elucidate the in vivo distribution of administered 
mesenchymal stem cells for the treatment of liver cirrhosis.  
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        The article entitled, “A physiologically based kinetic model for elucidating the in vivo 
distribution of administered mesenchymal stem cells” has been published by Scientific 
Reports, 2016; 6: 22293. The manuscript, figures and tables have been adjusted to fit the 
overall style of the Thesis and incorporated as this chapter. 
5.2 Abstract 
Although mesenchymal stem cells (MSCs) present a promising tool in cell therapy for 
the treatment of various diseases, the in vivo distribution of administered MSCs has still 
been poorly understood, which hampers the precise prediction and evaluation of their 
therapeutic efficacy. Here, we developed the first model to characterise the physiological 
kinetics of administered MSCs based on direct visualization of cell spatiotemporal 
disposition by intravital microscopy and assessment of cell quantity using flow cytometry. 
This physiologically based kinetic model was validated with multiple external datasets, 
indicating potential inter-route and inter-species predictive capability. Our results suggest 
that the targeting efficiency of MSCs is determined by the lung retention and interaction 
between MSCs and target organs, including cell arrest, depletion and release. By adapting 
specific parameters, this model can be easily applied to abnormal conditions or other types 
of circulating cells for designing treatment protocols and guiding future experiments. 
Key Words: Mesenchymal stem cells, Liver disease, Distribution, Modelling, Multiphoton 
microscopy 
 
5.3 Introduction 
        Mesenchymal stem cells (MSCs), also called multipotent mesenchymal stromal cells, 
are self-renewing, nonhematopoietic somatic stem cells comparable to embryonic stem 
cells in terms of their multipotency and proliferative and differentiation potential. Due to 
their multilineage differentiation potential and immunomodulatory properties, MSCs 
present a promising tool in cell-based therapy for treatment of various nonhematopoietic 
diseases, such as myocardial infarction, liver cirrhosis, spinal cord injury, cartilage damage 
and diabetes [1-3]. After the first clinical trial employing MSCs to treat osteogenesis 
imperfecta published in 1999 [4], the number of registered clinical trials significantly 
increased, reaching 344 in 2013 [5]. Restoring the viability and function of MSCs in 
anatomically complex organs (e.g. the liver, heart, and brain) remains a challenge for 
systematic MSC transplantation. Although functional improvements following the delivery 
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of MSCs have been extensively explored in various diseases, our current understanding of 
the in vivo behavior and distribution of administered MSCs is limited, which seems to 
hamper further transition of MSC transplantation from experimental trials to standard 
clinical procedures. Previous studies showed that most of MSCs were entrapped in the 
lung immediately after intravenous injection, with some MSCs undergoing apoptosis [6]. 
After about 10 min, these trapped MSCs gradually returned to the blood circulation and 
redistributed to other organs [7]. Finally only a small fraction of MSCs were found to 
survive, migrate to and engraft in the target organs. Thus, it would be important to 
characterize the in vivo distribution of MSCs following intravascular administration to 
predict their survival and homing to target organs [6]. 
        A number of published model have the potential to characterize the in vivo behavior 
of administered stem cells. The long-term replication, differentiation, or apoptosis of stem 
cells could be predicted by stochastic model [8, 9] or time-variant clustering model [10]. A 
computational cell motility model has been developed to probe the migration mechanism 
of cells [11]. And the population dynamics of administered cells may be predicted using a 
recently developed mathematical model [12]. However, none of the above-mentioned 
published models could elucidate the concentration-time profiles of administered cells in 
organs. There is still a lack of a proper model to characterize the in vivo distribution of 
administered stem cells. It has been reported that the dynamics of systematically 
administered MSCs were similar to that of inert micrometer-scale particles injected into the 
bloodstream of animals [13]. Therefore the complex, yet regulated, in vivo kinetics of 
administered MSCs are amenable to pharmacokinetic model building and analysis. During 
the past 30 years, physiologically based kinetic (PBK) models have been successfully 
applied to analyse the kinetics of small molecules, antibodies, nanoparticles and 
lymphocytes [14, 15]. Such model is based on the anatomical structure of the living 
systems, with each important organ regarded as an individual compartment. All 
compartments are connected by blood flow [14]. Compared to empirical kinetic models, 
PBK modeling has the potential for interspecies scaling, which allows prediction of 
compound pharmacokinetics in humans using animal data. By systematically examining 
the effects of changing individual model parameters, PBK models can identify key 
parameters and their values, and suggest possible strategies for improvements in 
biodistribution. Therefore, quantitatively analyzing the in vivo distribution of MSCs with 
PBK modeling has the potential to identify the barriers to MSCs delivery, and propose 
designs of new formulations and dosing regimens to maximize the therapeutic activity.  
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        In this study, we developed a simple PBK model to characterise the in vivo kinetics of 
MSCs from biodistribution data of green fluorescent protein (GFP) expressed MSCs 
intravenously injected into mice. Being the first effort to model the distribution of 
administered stem cells, this model invoked assumptions based on direct visualization of 
MSCs in specific organs at the cellular level using high resolution multiphoton microscopy. 
The utility of the model was examined across species and administration routes by 
extrapolation of this model to rats and humans, as well as to intra-hepatic arterial injection. 
The clinical utility of the model was also tested with data obtained from stem cell-based 
therapies to patients with liver cirrhosis. This PBK model provides a general framework for 
the study of in vivo distribution of therapeutic cells to design treatment protocols and to 
guide future experiments. 
5.4 Materials and Methods 
5.4.1 Cell preparations 
The mouse GFP-MSCs used in this study were kindly provided by Dr. Mike Doran 
(Queensland University of Technology). The MSCs were isolated, characterized and 
cultured from inbred C57BL/6 mice transgenic for GFP under the control of the ubiquitin 
promoter as previously described [16, 17]. All experiments involving MSCs were 
performed at passage 8-12, tested negative for mycoplasma contamination, and <80% 
confluence. The average diameter of suspended MSCs was measured from fifty different 
cells from twelve representative image fields. 
5.4.2 In vivo transplantation and imaging of MSCs 
Male 20-week-old BALB/c nude mice were purchased from the Animal Resource 
Centre (Perth, Western Australia). All animal procedures were approved by the Animal 
Ethics Committee of the University of Queensland and were carried out in accordance with 
Australian Code for the Care and Use of Animals for Scientific Purposes 8th edition. Mice 
were anaesthetized initially by an intraperitoneally injection of ketamine hydrochloride (80 
mg/kg) and xylazine (10 mg/kg). Body temperature was controlled by placing mice on a 
heating pad set to 37°C. 150 µl of a suspension of 5 × 105 MSCs was injected with a 27 
gauge needle through the tail vein. Prior to injection, the MSCs were maintained at 4°C, 
and the cells were gently resuspended with a pipette to ensure no aggregation before 
injection. 
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MPM was performed using the DermaInspect system (Jen-Lab GmbH, Jena, 
Germany) equipped with an ultrashort (85 fs pulse width) pulsed mode-locked 80-MHz 
titanium sapphire laser (MaiTai, Spectra Physics, Mount View, CA, USA). The excitation 
wavelength was set to 740 nm for organ autofluorescence and 900 nm for GFP signals, 
with emission signal ranges of 350 to 450 nm and 450 to 515 nm established respectively 
through the use of BG39 bandpass filters (BG39, Schott glass color filter, Schott MG, 
Mainz, Germany). Images were recorded with oil-immersion 40× objectives (Carl Zeiss, 
Germany). The laser power was set to 15 mW for 40×magnification imaging, and the 
acquisition time for obtaining the images was 7.4 seconds per frame. Intravital imaging of 
the mouse liver was performed as previously described [18, 19]. Twenty-four images from 
twelve non-overlapping fields were collected per mouse (n = 5) without the use of 
randomization and blinding. Normal saline was used to keep the liver and other organs 
moist and attached to the cover glass throughout the experiment. Analysis and overlay of 
the fluorescence intensity images was done using ImageJ 1.44p (National Institutes of 
Health, USA). The diameter of cells was measured along three different arbitrary lines 
within a cell, and tested on eighteen different cells from six representative image fields. 
Organ specimens from sites of MPM imaging were fixed in 4% buffered formalin and 
embedded in paraffin. Serial sections were obtained for Hematoxylin & Eosin (H&E) stain 
to evaluate histopathologic features. The OlyVIA software 2.6 (Olympus, Münster, 
Germany) was used to visualise and scan the slides.  
5.4.3 Measurement of donor MSCs in recipient organs 
         Animals (n = 5) were sacrificed at designated times (5 min, 15 min, 1, 3, 10, and 20 
hour post-injection). The blood and major organs were removed and weighed. Red blood 
cells were lysed and single-cell suspensions of organs were obtained as previously 
described [20]. The total number of GFP-MSCs in each single-cell suspension of organs 
was measured and analysed by flow cytometry using a FACS Calibur (Accuri C6, BD, San 
Jose, CA, USA) as previously described [21]. As negative controls, single-cell suspensions 
of organs from naive mice were run in parallel. Light scattering parameters were set to 
exclude dead cells and debris. 
5.4.4 Mathematical description of the model 
         The model structure was based on published PBK models simulating the distribution 
(using distribution coefficient) and uptake-release-excretion processes (using uptake, 
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release and excretion rate constant) of inert nanoparticles [22]. The model assumes a fast 
process of MSCs transported into various levels of blood vessels in organs. The partition 
coefficient P is used to correlate the concentration of MSCs between the blood within the 
organ and the venous blood leaving the organ. Given that the microvascular environment 
varies between organs, the partition coefficient is assumed to be different between organs. 
The equation describing this correlation is: 
CVt =
𝐶V_t
𝑃t
                                                                         (1) 
 
where CVt (cell/L) is the concentration of MSCs in the venous blood leaving the organ t, 
CV_t (cell/L) is the concentration of MSCs in the vascular space within the organ t, Pt 
(unitless) is the partition coefficient of the organ t. 
        Since a fraction of MSCs could be arrested in organs and isolated from blood 
circulation, these MSCs are described separately as in the extravascular space of organ. 
In the blood and organs, elimination of MSCs after depletion occurs as a clearance route 
from the body. The arrest-release-depletion approach of MSCs was described as a first-
order process. The equations describing these processes are:  
For vascular space 
VV_t
𝑑𝐶V_t
𝑑𝑡
= Qt(CA − CVt) − Karrest_tCV_tVV_t + Krelease_tAE_t                  (2) 
For the arrested MSCs as in the extravascular space 
𝑑AE_t
𝑑𝑡
= Karrest_tCV_tVV_t − Krelease_tAE_t − Kdepletion_tAE_t                      (3) 
 
VV_t (L) is the volume of blood vessels in the organ t, Qt (L/h) is the blood flow to the organ 
t, CA (cell/L) is the concentration of MSCs in the arterial blood, AE_t (cell) is the amount of 
arrested MSCs and isolated from blood circulation as in the extravascular space of organ t, 
Karrest_t (h-1) is the arrest rate constant of MSCs in the organ t, Krelease_t (h-1) is the 
release rate constant of MSCs in the organ t, and Kdepletion_t (h-1) is the depletion rate 
constant of MSCs in the organ t. Mass balance equations used in the model are presented 
in the Supplementary Note. 
 
5.4.5 Implementation and parameterization of the model 
         The PBK model was implemented in Berkeley Madonna version 8.3.18 (Berkeley, 
CA, USA). Mass balance equations used in the model are presented in the supplementary. 
All physiological parameter values (body weight, organ volume, blood volume and blood 
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flow) were from the literature and are given in Table S1. MSC-specific parameters 
(partition coefficient, arrest rate constant, release rate constant and depletion rate 
constant) were optimized by using both curve fitter in Berkeley Madonna automatically and 
a manual approach to obtain a visually reasonable fit to the experimental biodistribution 
data of GFP- MSCs intravenously injected into mice. 
5.4.6 Sensitivity analyses 
         To determine the effect of the parameters on the model solution, sensitivity analysis 
was performed for the parameters in the target organs. The value of each parameter was 
increased by 0.1%, the model simulations were repeated, and the new MSCs 
concentrations noted. The relative sensitivity coefficients for significant parameters were 
calculated using the following equation: 
Relative sensitivity coefficient =
𝑑𝐶/𝐶
𝑑𝑃/𝑃
                                                (4) 
where C (cell/L) is the concentration of MSCs, and P is the parameter value. A positive 
RSC indicates a direct association between the model output and the corresponding 
parameter, while a negative RSC suggests the model output is inversely correlated with 
the specific parameter. The RSC values with absolute values higher than 0.5 are 
considered as highly sensitive. 
5.4.7 Model evaluation with independent data 
         The predictive capability of our PBK model was evaluated with external datasets 
from different species [7, 23-26]. To facilitate comparisons among the various studies, all 
concentrations were normalized to the number of MSCs per kg of organ. The physiological 
parameter values of rats and humans were obtained from the literature and are given in 
Table S1. MSC-specific parameters were assumed to be the same for mice, rats and 
humans. The overall goodness-of-fit between predicted and measured values was further 
analyzed with linear regression. To compare the predictive capability of model with 
different parameters, bias (mean prediction error [MPE]) and precision (mean absolute 
prediction error [MAPE]) are calculated with 95% confidence intervals (CIs) using the 
following equation: 
𝑀𝑃𝐸 =
∑(𝑀𝑝𝑟𝑒𝑑−𝑀𝑜𝑏𝑠)
𝑁
                                                         (5) 
𝑀𝐴𝑃𝐸 =
∑ |𝑀𝑝𝑟𝑒𝑑−𝑀𝑜𝑏𝑠|
𝑁
                                                        (6) 
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where Mpred is the predicted value, Mobs is the observed value, and N is number of time 
points. The statistical analysis was done using GraphPad Prism v 6.04 (GraphPad 
Software Inc., La Jolla, California). 
 
5.5 Results  
5.5.1 Disposition of MSCs at organ level 
The spatiotemporal disposition of GFP-MSCs in organs at the cellular level was 
explored using multiphoton microscopy (MPM). Fig. 5.1A and 5.1B shows representative 
images of MSCs distribution in lung and liver at 30 min after intravenous injection. The 
MSCs were quickly observed in the microvessels of the lung and liver, instead of 
extravascular migrating into the surrounding collagens or alveoli of the lung and 
parenchyma of the liver. The size of MSCs was determined to be 20.1 ± 1.2 µm in mouse 
blood using MPM (Supplementary Fig. S5.1), and confirmed by bright-field microscopy 
(22.0 ± 2.6 µm, Supplementary Fig. S5.2). Some MSCs became passively entrapped in 
small-diameter blood vessels, and some were found to accumulate and move in vessels 
with diameters greater than those of MSCs (Fig. 5.1B), suggesting the existence of both 
passive and active organ retention of MSCs. MSCs with smaller sizes (around 10 µm) 
were observed in organ capillaries (Fig. 5.1A), suggesting the possibility of MSC 
deformability which has been reported previously [27-29]. Few MSC was detected 
extravascular migrating up to 24 hours following intravenous injection. Fig. 1C depicts the 
depletion process of one representative MSC in liver captured by real-time intravital 
imaging. After entrapped into the junction of the terminal portal venule and sinusoids (30 
minutes post-injection), cell fragmentation was gradually observed with reduced 
fluorescence due to cell depletion.  
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Figure 5.1 Disposition of MSCs at organ level. (A) At 30 minutes post injection, the MSCs 
were found entrapped in the microvessels of the lung while no cell was found in the 
surrounding collagens or alveoli in the lung. Some MSCs less than 10 µm in diameter and 
may pass through the capillaries. (B) At 30 minutes post injection, some MSCs in liver 
were found accumulated and moving in vessels with diameters greater than those of 
MSCs and no cell was found extravasate into the liver parenchyma. (C) The depletion of 
MSC in the liver after intravenous injection. After entrapped at the junction of the terminal 
portal venule and sinusoids at 30 minutes post-injection, one MSC slowly became 
fragmented with reduced fluorescence suggestive of depletion. No MSCs was observed to 
cross the vessel membrane to the liver parenchyma. Images were recorded at λExc/λEm: 
740/350 to 450 nm for the endogenous autofluorescence of the lung and liver (red, left 
column), and λExc/λEm: 900/450 to 515 nm for fluorescence of GFP (green, middle column). 
The right column represents fused images. Scale bar: 40 μm, and the white arrow points 
towards the MSCs with smaller sizes. A, alveoli; V, vessels; P, parenchyma; T, terminal 
portal venule. 
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5.5.2 Development of PBK model 
        The PBK model of MSCs in mice was developed based on the above observations 
and on the published intravital microscopic details of administered MSCs [27-29]. After 
intravenous injection, MSCs were transported to blood vessels of organs by organ blood 
flow via the systemic circulation. This process is assumed to be very fast. As shown in Fig. 
2A, after reaching the organs, some MSCs became entrapped in microvessels due to their 
large sizes or temporarily adhered to the endothelial wall. A portion of these entrapped 
MSCs could be released back to the blood circulation or eliminated after depletion. These 
arrest-release-depletion processes were assumed to follow first-order kinetics with rate 
constants of karrest, krelease, and kdepletion, respectively. Tissue integration and differentiation 
of the arrested MSCs were not included in the model as these processes were much 
slower [30, 31] and had less impact on the MSC circulation and distribution at the organ 
level in the short term. All MSCs were assumed to act independently with no intercellular 
feedback loops or obligatory connections. For example, the entrapment of one MSC would 
not trigger the apoptosis or release of another. In summary, the in vivo kinetics of MSCs in 
this model was assumed to be governed by two processes: (1) transport to the organ via 
systematic circulation; (2) interaction with blood vessels of organs. 
To build the PBK model, the whole body was separated into eight compartments: 
arterial blood, venous blood, lungs, spleen, liver, kidneys, heart and the rest of body. All 
compartments were interconnected via the systemic blood circulation (Fig. 5.2B). Key 
components included in the model were species-specific physiological parameters (body 
weight, organ volume and blood flow, given in Supplementary Table S5.1) and MSC-
specific parameters (partition coefficient, arrest rate constant, release rate constant and 
depletion rate constant). 
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Figure 5.2 Hypothesis and schematic diagram of the PBK model for the in vivo fate of 
MSCs. (A) Assumptions for modeling based on direct visualization of MSCs in specific 
organs at the cellular level using high resolution multiphoton microscopy. After intravenous 
injection, MSCs were transported to blood vessels of organs via systemic circulation. After 
reaching the organs, some MSCs became entrapped in microvessels due to large sizes or 
adhered to the endothelial wall. These MSCs could be released back to blood circulation 
or eliminated after depletion. The process of tissue integration and differentiation of the 
arrested MSCs was much slower extending from 24 to 72 hours post-injection. (B) 
Schematic diagram of the PBK model for the in vivo fate of MSCs. Solid arrows indicate 
blood flow, dashed grey arrows indicate the depletion of MSCs and grey boxes indicate 
the arrested MSCs isolated from blood circulation as in the extravascular space of organ. 
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5.5.3 Comparison of PBK model predictions with experimental data 
After intravenous injection, the time profile of MSC levels in venous blood exhibited a 
two phase decay corresponding to a fast distribution and a relative slow elimination 
process. Lung, liver, spleen and kidney were major organs of MSC accumulation. MSCs 
displayed different patterns of concentration-time profiles in these organs. As shown in Fig. 
3, the observed time profiles of MSCs concentration in mouse blood and organs were 
adequately described by the developed PBK model with an overall regression coefficient 
(R2) of 0.966 (Supplementary Fig. S5.3), indicating high goodness-of-fit of model 
calibration results. However, despite the adequate overall predictions, it should be noted 
that the model predicted a rapid decrease of MSC concentration in blood within 5 min after 
injection. There is a lack of experimental data at this early time point to confirm this, which 
requires further experiments to either validate this prediction or revise the model 
accordingly. 
Table 1 summarized the MSC-specific parameters for each organ. The highest arrest 
rate constant was obtained for the lung estimated by curve fitting (5.434 h-1), indicating 
that MSCs are predominantly entrapped in the lung after in vivo administration. Blood 
showed the highest depletion rate constant (0.636 h-1), suggesting its role as major 
elimination organ. The depletion rate constant in kidney was found to be highest among all 
organ compartments (0.151 h-1), which was consistent with the results from whole-body 
imaging and radioactivity counting of urine after injection of 99mTc labeled MSCs [24]. Our 
estimates suggest that about 28% of the transplanted MSCs survive in vivo 24 hours after 
intravenous injection. Similar survival rate have been obtained by intravital imaging of rat 
cremaster muscle microcirculation to track intraarterially delivered MSCs [27].  
    To determine the effect of each parameter on the model simulation, a sensitivity 
analysis was performed. The relative sensitivity coefficient (RSC) for the concentration of 
MSCs in liver and heart are shown in Supplementary Fig. S5.4, because liver cirrhosis 
and myocardial infarction are two common diseases that have been treated with MSCs 
clinically. We selected 24 hours post-injection, when the amount of circulating MSCs 
decreased to a relatively steady state. The concentration of MSCs in the liver at 24 h post 
injection was highly sensitive to the depletion rate constant of liver, the release rate 
constant of lung, the partition coefficient and arrest rate constant of liver and lung. Similar 
effects of these parameters on the heart were observed. The depletion and arrest rate 
constant of heart, the arrest rate constant of lung, and the partition coefficient of heart and 
lung had a high impact on the concentration of MSCs in heart at 24 h post injection. 
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Figure 5.3 Model calibration results with experimental data. Mice were intravenously 
injected with 5 × 105 MSCs (n = 5). The solid line in each panel represents the 
concentration-time profile of the MSCs simulated by the PBK model while the closed 
circles represent measured biodistribution data. Concentration of the MSCs is expressed 
as number of cells per kilogram of tissue. The data are expressed as mean ± s.d. The 
initial concentrations for organs (0 cell/L) are not shown because a base-10 log scale is 
used for the concentration. 
5.5.4 Model evaluation with independent rodent data 
        The validity of the PBK model was first evaluated with data from Shim et al. [26] and 
Lee et al. [7] where MSCs (5 × 105 and 2 × 106 cells) were intravenously administered to 
normal and diseased mice. All physiological parameters and MSC-specific parameters in 
the model were maintained constant. As shown in Fig. 5.4A, C and D, the model 
adequately predicted the MSC concentrations in blood in normal mice from the dataset of 
Shim et al. [26], and MSC concentrations in lung and heart in normal mice from the 
dataset of Lee et al. [7]. However, as shown in Fig. 5.4B, the predicted MSC concentration 
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in blood only slightly increased at about 3 min post-injection, while Lee et al. observed a 
much more substantial reappearance of MSCs in blood (2% to 3% of administered MSCs) 
after a lag period about 30 min [7]. A possible reason for this difference could be the 
different methods of MSC quantification, where the observed data were measured by 
quantitative assays for DNA of MSCs and our model was based on the data from flow 
cytometry analysis. Another reason is that mechanistic considerations, such as cell 
aggregation, changes in flow to organs, were not included in modeling, while these 
mechanisms might become more relevant to MSC distribution when higher concentration 
are administered. In the dataset from Shim et al. [26], the distribution of MSCs did not 
differ significantly between normal and osteoarthritis-induced mice. However, the model 
underestimated the MSC concentration in the heart with myocardial infarction from the 
dataset of Lee et al. [7] (Fig. 5.4D), indicating the disease effect on MSC distribution. We 
then recalibrated the model to data from mice with myocardial infarction [7], to estimate the 
diseases-specific heart-related parameters (Supplementary Table S5.2). As shown in 
Fig. 5.4D, the MSC concentration in the infarcted hearts was more accurately predicted by 
the same PBK mode with re-estimated diseased-specific parameters than with original 
parameters (the comparison of precision is shown in Supplementary Table S5.3). The re-
estimation results indicated that higher concentration of MSC is related to higher arrest 
and less depletion of MSC in heart in disease status.  
To further evaluate the predictive applicability of the PBK model across species, 
simulations were compared with published experimental data for rat [24]. Physiological 
parameters of rats (given in Supplementary Table S5.1) were obtained from literature 
[32, 33]. MSC-specific parameters in the model were maintained constant. As shown in 
Fig. 5.5, the MSC concentrations in the lung, liver, spleen, kidneys and heart were 
predicted adequately by the model, but the blood levels were underestimated. It should be 
noted that MSCs in that study were 99mTc labeled and distribution was measured by 
nuclear imaging. Therefore, residual radioactivity of cell fragments in blood before 
excretion may result in overestimation of MSC concentration in nuclear imaging. In 
contrast, our model was based on the data from flow cytometry analysis, which largely 
reflected the concentration of live cells. Overall, there was a good correlation (R2 = 0.922) 
between PBK model estimates and independent rodent data (Supplementary Fig. S5.5), 
indicating that the model shown here is applicable to predict the in vivo distribution of 
administered MSCs across rodents. However, the time courses of this datasets have only 
two data points (2 hours and 20 hours) for each organ. More detailed data are needed to 
adequately evaluate the potential inter-species predictive capability of this model. 
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Table 5.1 MSC-specific parameters used in the PBK model estimated by curve fitting 
Parameter 
(unit) 
Description Blood Lung Liver Spleen Kidney Heart Rest of 
body 
P (unitless) Partition 
coefficients 
- 742.733 262.699 1633.24 305.351 3.097 6.765 
Karrest (h-1) Arrest rate 
constant 
- 5.434 1.395 0.608 1.727 1.251 0.143 
Krelease (h-1) Release rate 
constant 
- 0.108 0.066 0.856 0.054 0.016 0.957 
Kdepletion (h-1) Depletion rate 
constant 
0.636 0.0589 0.060 0.002 0.151 0.039 0.148 
 
 
Figure 5.4 Model evaluation results with independent external datasets from mice. (A) 
Mice were intravenously injected with 5 × 105 MSCs [26] (n = 5). (B, C and D) Mice were 
intravenously injected with 2 × 106 MSCs [7] (n = 6). The solid line in each panel 
represents the concentration-time profile of the MSCs simulated by the PBK model while 
the closed circles represent measured biodistribution data. Concentration of the MSCs is 
expressed as number of cells per kilogram of tissue. The data are expressed as mean ± 
s.d. The initial concentrations for organs (0 cell/L) are not shown because a base-10 log 
scale is used for the concentration. 
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Figure 5.5 Model evaluation results with independent external datasets from rats. Rats 
were intravenously injected with 3.2 × 106 MSCs [24] (n=9). The solid line in each panel 
represents the concentration-time profile of the MSCs simulated by the PBK model while 
the closed circles represent measured biodistribution data. Concentration of the MSCs is 
expressed as number of cells per kilogram of tissue. The data are expressed as mean ± 
s.d. The initial concentrations for organs (0 cell/L) are not shown because a base-10 log 
scale is used for the concentration. 
5.5.5 Model predicting the in vivo distribution of therapeutic stem cells in humans 
        This model was used to predict the in vivo distribution of the therapeutic stem cells in 
patients with liver cirrhosis after intravenous or intra-hepatic arterial injection. Physiological 
parameters of humans (given in Supplementary Table S5.1) were obtained from literature 
[32, 33, 34], MSC-specific parameters in the model were maintained constant. As shown in 
Fig. 6A, our model suggests that the time profiles of MSC concentration in liver 
significantly differ between patients after intravenous or intra-hepatic arterial injection of 
the same number (8.5 × 108) of MSCs. The model successfully predicted the proportion of 
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bone marrow-derived mononuclear cells (BMMCs) in the liver to the whole body at 3 and 
24 hours after injection for the data from Couto et al. [23] (Fig. 5.6B). However, it 
underestimated the proportion of MSCs in the liver to the whole body after intra-hepatic 
arterial injection for the data from Gholamrezanezhad et al. [25] (Fig. 5.6C). We then 
recalibrated the model to data from human with liver cirrhosis [25], to estimate the 
diseases-specific liver-related parameters (Table S5.2). As shown in Fig. 5.6D, the MSC 
concentration in the cirrhotic liver was more accurately predicted by the same PBK mode 
with re-estimated diseased-specific parameters than with original parameters (the 
comparison of precision is shown in Supplementary Table S5.3). The re-estimation 
results indicated that higher concentration of MSC is related to higher partition and arrest 
of MSC in liver in disease status. 
 
Figure 5.6 Model evaluation results with independent external datasets from humans. (A) 
The PBK model suggests that the time profiles of MSC concentration in liver significantly 
differ between patients after intravenous or intra-hepatic arterial injection of the same 
number (8.5 × 108) of MSCs. (B) Patients were intra-hepatic arterially injected with an 
average of 8.5 × 108 radiolabeled BMMCs [23] (n = 8). (C and D) Patients were intra-
hepatic arterially injected with an average of 3.2 × 108 radiolabeled MSCs for 24 hours and 
10 days, respectively [25] (n = 4). The residual radioactivity in the liver is expressed as the 
proportion of the whole body radioactivity. The solid line in each panel represents the 
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concentration-time profile of the cells simulated by the PBK model while the closed 
squares represent measured biodistribution data. The data are expressed as mean ± s.d. 
5.6 Discussion 
Although hundreds of studies have reported the cell biodistribution in the field of stem 
cell-based therapy, no integrating model characterizing the in vivo kinetics of these cells 
has been developed with respect to pharmacological effects and therapeutic thresholds. In 
the present study, we developed a model based on direct visualization of GFP-labeled 
MSCs disposition in the mice at the cellular level in specific organs. Importantly, the mouse 
cells used in this study were expanded to a similar size as the human MSCs currently 
used in clinical trials. Compared with the previously published PBK model of lymphocytes 
[15], our model is especially applicable to circulating cells with large sizes (MSCs or 
cancer cells are 1.5 to 4 times larger than lymphocytes). This model is more useful for 
clinical applications since a less complicated framework and parameters were employed. 
In the future, the predictive power of this model is likely to improve with the incorporation of 
new parameter values or advanced microscopic details as they become available. 
One of the advantages of PBK modeling over traditional empirical kinetic modeling is 
the ability to provide time profiles of cell concentration in individual organs. The in vivo 
distribution of MSCs characterized mathematically in the present study will better inform 
the dosing regimens of cell-based therapies. For example, it may be expected that higher 
administered numbers of MSCs should result in more MSC engraftment and better 
functional outcomes. However, in a rat model of brain injury, no additional enhancement of 
neurological function was observed after increasing the dose of intravenous injected MSCs 
by 3-fold [35]. Thus, simply increasing the number of delivered cells may not improve the 
overall outcome. The sensitivity analysis of our PBK model showed that the accumulation 
of MSCs in the lung adversely affected the delivery of therapeutic cells to other target 
organs, evident by the concentrations of MSCs in the target organs were sensitive to 
changes in the partition coefficient, arrest or release rate constant in the lung. The partition 
coefficient, arrest and depletion rate constant in target organs also had a high impact on 
the concentration of MSCs. Thus, instead of increasing the dose, possible strategies to 
further improve the target efficiency of cell-based therapies would be bypassing the initial 
lung entrapment and enhancing organ-specific capture by modulating cell surface 
properties. Our model as well as some published data [7, 24, 26] revealed slow MSC 
elimination rates in blood, liver, kidney and heart. However, the cell quantity is influenced 
by the sensitivity and specificity of measurement methods. The background noise of 
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signals in the recipient organs could be misinterpreted as slow MSC elimination rates. It is 
critical that future MSC experiments use more advanced measurement methods for 
modelling.  
Administration of MSCs into the arterial supply of the liver was examined in this study 
as an alternative route of intravenous injection to bypass lung entrapment. The inter-route 
extrapolation of this PBK model suggests that accumulation of MSCs in the liver 
significantly differs after intravenous and intra-hepatic arterial injection. Our PBK model 
confirmed that direct delivery of MSCs to the target organs may improve the therapeutic 
efficacy by increasing the accumulation of surviving cells in those organs. Compared to 
intravenous injection, transplantation via hepatic artery or portal vein could increase the 
amount of MSCs in the liver at 24 hours post-injection by 4-fold in humans (Fig. 6A), in 
agreement with the therapeutic efficacy study of the MSCs treatment of fulminant hepatic 
failure in pigs [36]. Our PBK model also allows the scale-up from the mice data to humans. 
In many studies on cell therapy, an accurate concentration of cells in organs is not 
available from humans [37]. One should be cautious in direct translation of the distribution 
results from mice to humans due to different concentration-time profiles of MSCs in organs 
between species. This PBK model could provide more accurate prediction by scaling up 
the profile from mice to human.  
There is substantial evidence that administered MSCs would accumulate within sites 
of disease or injury. Local changes in microvessels and organ-derived attractants have 
been reported to affect the arrest and entrapment of MSCs in diseased organs [28], while 
the time profiles of cell concentrations in unaffected organs may only slightly decrease 
[24]. Thus, parameter values of diseased organs in the PBK model would be different from 
normal organs. In the present model, MSC-specific parameters of diseased organs for 
myocardial infarction and liver cirrhosis were optimized separately from respective 
datasets, because these parameters were considered to be the most influential in the in 
vivo distribution of MSCs in disease, while other less influential parameters were kept the 
same. It would be of importance to investigate the MSC-specific parameters of target 
organs for each main type of diseases in the future. 
In summary, we present the first model for characterizing and predicting the in vivo 
distribution of administered MSCs. Key ingredients in the model are species-specific 
physiological parameters (body weight, organ volume, blood volume and blood flow) and 
cell-specific parameters (partition coefficient, arrest rate, release rate and depletion rate). 
This model has been validated with multiple external datasets under widely different 
conditions and in different species, indicating potential inter-route and inter-species 
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predictive capability. Based on our analysis, possible strategies to improve efficiency of 
cell-based therapies include bypassing the initial lung entrapment with administration to 
the arterial supply of target organs and enhancing organ-specific capture by modulating 
cell surface properties. This PBK model can be extended to other types of circulating cells 
by adapting the cell-specific parameters, and provides a general framework for the study 
of the in vivo distribution of therapeutic cells to design treatment protocols. 
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Supporting Information 
 
Supplementary Figures 
 
Figure S5.1 Morphology of MSCs in vitro imaged by MPM. (A) MSCs proliferated in the 
culture plate had a typical fibroblast-like morphology and were evenly distributed on the plate. 
(B) The suspended MSCs in mouse blood. Images were recorded at λExc/λEm: 740/350 to 450 
nm for the endogenous autofluorescence of MSCs (red, left column), and λExc/λEm: 900/450 to 
515 nm for fluorescence of GFP (green, middle column). The right column represents fused 
images. Scale bar: 40 μm. 
 
 
Figure S5.2 Morphology of MSCs in vitro imaged by bright-field microscopy. The MSCs 
were suspended in PBS. Scale bar: 40 μm. 
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Figure S5.3 Goodness-of-fit plot of model calibration. Model predictions and experimental 
data were analysed using linear regression. The linear regression coefficient (R2) is 0.966 
(n = 36). 
 
 
Figure S5.4 Sensitivity analyses for the MSC concentration in mouse liver and heart. 
Positive values indicate that MSC concentration increases when the parameter value 
increases, while negative values indicate that MSC concentration decreases when the 
parameter value increases. P, partition coefficient; Karrest, arrest rate constant; Krelease, 
release rate constant; Kdepletion, depletion rate constant; Lu, lung; L, liver; K, kidney; H, 
heart. 
 
110 
 
 
Figure S5.5 Goodness-of-fit plot of model evaluation. Model predictions and experimental 
data from independent external studies [1-5] were analyzed using linear regression. The 
linear regression coefficient (R2) is 0.922 (n = 41). 
 
Supplementary Tables 
Table S5.1 Physiological parameters used in the PBK model 
Parameter (unit) Mouse Rat Human 
Body weight (kg) 0.02 0.25 70 
Cardiac output (L/hour/kg0.75) 16.5 15 12.89 
Blood flow to organ (fraction of cardiac output, unitless)    
Lung 1.00 1.00 1.00 
Liver 0.161 0.25 0.227 
Spleen 0.011 0.01125 0.01205 
Kidney 0.091 0.141 0.175 
Heart 0.035 0.035 0.037 
Organ volumes (fraction of body weight, unitless)    
Lung 0.007 0.005 0.014 
Liver 0.055 0.034 0.026 
Spleen 0.005 0.0025 0.0026 
Kidney 0.0017 0.007 0.00448 
Heart 0.004 0.0022 0.0048 
Blood 0.0085 0.074 0.079 
Volume fraction of blood in organs (unitless)    
Lung 0.50 0.36 0.30 
Liver 0.31 0.21 0.11 
Spleen 0.17 0.22 0.51 
Kidney 0.24 0.16 0.36 
Heart 0.26 0.26 0.07 
Rest of body 0.04 0.04 0.01  
All values are from the literature [6-8]. 
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Table S5.2 Disease-specific parameters of target organs estimated by curve fitting 
Parameter 
(unit) 
Description Liver (Cirrhosis) Heart (MI) 
P (unitless) Partition coefficient 376.074 2.311 
Karrest (h-1) Arrest rate constant 5.793 6.823 
Krelease (h-1) Release rate constant 0.094 0.025 
Kdepletion (h-1) Depletion rate 
constant 
0.098 0.029 
MI: myocardial infarction. 
 
Table S5.3 Predictive capability of the PBK model with original or disease-specific 
parameters 
Variable Disease Parameter Bias (MPE, SEM) Precision (MAPE, SEM) 
MSC 
concentrati
on of heart 
MI Original 1.079 × 107 (7.898 × 
106) 
1.113 × 107 (7.659 × 
106) 
  Disease-specific 2.975 × 106 (4.778 × 
106) 
7.361 × 106 (4.038 × 
105) 
Proportion 
of MSCs in 
the liver  
Cirrhosis Original -1.186 (0.3817) 1.242 (0.3343) 
  Disease-specific 0.060 (0.3885) 0.690 (0.1812) 
MI: myocardial infarction  
MPE: mean prediction error 
MAPE: mean absolute prediction error 
SEM: standard error of the mean 
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Supplementary equations 
Mass balance equations 
For venous blood: 
VVb
𝑑𝐶𝑉Vb
𝑑𝑡
= (Q
L
CVL +QSCVL + QKCVK + QHCVH + QBoCVBo) − QLuCVVb
− Kdepletion_vVVbCVVb 
 
For arterial blood: 
VA
𝑑CA
𝑑𝑡
= QLu(CV_Lu − CA) 
 
For lung: 
CVLu =
𝐶V_Lu
𝑃Lu
 
For vascular space 
VV_Lu
𝑑𝐶V_Lu
𝑑𝑡
= QLu(CVVb − CVLu) − Karrest_LuCV_LuVV_Lu + Krelease_LuAE_Lu 
 
For the arrested MSCs as in the extravascular space 
𝑑AE_Lu
𝑑𝑡
= Karrest_LuCV_LuVV_Lu − Krelease_LuAE_Lu − Kdepletion_Lu × AE_Lu 
 
MSC concentration in the lung is given by: 
CTotal_Lu =
𝐶V_LuVV_Lu + AE_Lu
𝑉Lu
 
 
For liver: 
CVL =
𝐶V_L
𝑃L
 
For vascular space 
VV_L
𝑑𝐶V_L
𝑑𝑡
= QLCA + QSCV_S − (QL + QS)CV_L
− Karrest_LCV_LVV_L + Krelease_LAE_L 
 
For the arrested MSCs as in the extravascular space 
𝑑AE_L
𝑑𝑡
= Karrest_LCV_LVV_L − Krelease_LAE_L − Kdepletion_L × AE_L 
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MSC concentration in the liver is given by: 
CTotal_L =
𝐶V_LVV_L + AE_L
𝑉L
 
 
For spleen: 
CVS =
𝐶V_S
𝑃S
 
For vascular space 
VV_S
𝑑𝐶V_S
𝑑𝑡
= QS(CA − CVS) − Karrest_SCV_SVV_S + Krelease_SAE_S 
 
For the arrested MSCs as in the extravascular space 
𝑑AE_S
𝑑𝑡
= Karrest_SCV_SVV_S − Krelease_SAE_S − Kdepletion_S × AE_S 
 
MSC concentration in the spleen is given by: 
CTotal_S =
𝐶V_SVV_S + AE_S
𝑉S
 
 
For kidney: 
CVK =
𝐶V_K
𝑃K
 
For vascular space 
VV_K
𝑑𝐶V_K
𝑑𝑡
= QK(CA − CVK) − Karrest_KCV_KVV_K + Krelease_KAE_K 
 
For the arrested MSCs as in the extravascular space 
𝑑AE_K
𝑑𝑡
= Karrest_KCV_KVV_K − Krelease_KAE_K − Kdepletion_K × AE_K 
 
MSC concentration in the kidney is given by: 
CTotal_K =
𝐶V_KVV_K + AE_K
𝑉K
 
 
For heart: 
CVH =
𝐶V_H
𝑃H
 
For vascular space 
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VV_H
𝑑𝐶V_H
𝑑𝑡
= QH(CA − CVH) − Karrest_HCV_HVV_H + Krelease_HAE_H 
 
For the arrested MSCs as in the extravascular space 
𝑑AE_H
𝑑𝑡
= Karrest_HCV_HVV_H − Krelease_HAE_H − Kdepletion_H × AE_H 
 
MSC concentration in the heart is given by: 
CTotal_H =
𝐶V_HVV_H + AE_H
𝑉H
 
 
For the rest of the body: 
CVBo =
𝐶V_Bo
𝑃Bo
 
For vascular space 
VV_Bo
𝑑𝐶V_Bo
𝑑𝑡
= QBo(CA − CVBo) − Karrest_BoCV_BoVV_Bo + Krelease_BoAE_Bo 
 
For the arrested MSCs as in the extravascular space 
𝑑AE_Bo
𝑑𝑡
= Karrest_BoCV_BoVV_Bo − Krelease_BoAE_Bo − Kdepletion_Bo × AE_Bo 
 
MSC concentration in the rest of body is given by: 
CTotal_Bo =
𝐶V_BoVV_Bo + AE_Bo
𝑉Bo
 
 
Nomenclature (units) 
AE: Amount of arrested MSCs as in the extravascular space of each compartment (cell) 
CTotal: Average MSC concentration of each compartment (cell/kg) 
CV: MSC concentration in the vascular space of each compartment (cell/kg) 
CV: MSC concentration in the venous blood (cell/kg) 
Karrest: Arrest rate constant of MSCs (h-1) 
Krelease: Release rate constant of MSCs (h-1) 
Kdepletion: Depletion rate constant of MSCs in the organ (h-1) 
P: Partition coefficient (unitless) 
Q: Blood flow to each organ (L/h) 
V: Total volume of each compartment (L) 
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VV: Volume of vascular space of each compartment (L) 
 
Subscripts 
Vb: Venous blood 
A: Arterial blood 
Lu: Lung 
L: Liver 
S: Spleen 
K: Kidney 
H: Heart 
Bo: The rest of body 
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Chapter 6  
Conclusion and future directions 
 
6.1 Summary of Findings 
        The light based systems, multi-photon (MPM) and fluorescence lifetime imaging 
(FLIM), now provide mini-invasive quantitative imaging of fluorescent molecules in in situ 
and in vivo biological tissues and organs - in space (three dimensions), in time, in spectra, 
in lifetime and in fluorescence anisotropy (total of 7 dimensions). However, currently, their 
application in the liver is limited. This PhD project has advanced the application of MPM-
FLIM for diagnosis of liver diseases and prediction of treatment responses. The main 
achievements include three aspects:  
        1. A reliable and standardised method of stain-free and real-time histology for 
diseased liver has been established based on optical biopsy using MPM-FLIM (Chapter 3). 
Histopathological hallmarks of fibrotic liver, fatty liver, cancerous liver and liver with 
ischemia-reperfusion injury have been directly visualised by MPM-FLIM in vivo without 
biopsy or administration of fluorescent dyes. The acquired images were comparable with 
conventional histology, but provided additional information (e.g. redistribution of stellate 
cell as revealed by autofluorescence and lifetime changes), which cannot be obtained from 
conventional histology. MPM-FLIM has potential to serve as a diagnostic tool for human 
liver diseases in the future. 
        2. The oxidative stress of hepatocytes during liver injury has been quantified in vivo 
using MPM-FLIM (Chapter 4). Oxidative stress reflects an imbalance between reactive 
oxygen species (ROS) and antioxidants. It is an early unifying event in the development 
and progression of various diseases and as a direct and mechanistic indicator of treatment 
response. The oxidative stress endpoints can report early and molecular changes induced 
by treatment, and have potential to serve as powerful biomarkers of drug response. 
However, highly reactive and short-lived nature of ROS and antioxidant limited 
conventional detection agents, which are influenced by many interfering factors. In 
Chapter 4, the fluctuations of cellular oxidative stress were visualised during liver injury at 
the single cell-level resolution using MPM after injection of specific ROS and GSH 
detection probes. By combining fluorescence intensity imaging and FLIM, the changes of 
ROS and GSH levels in the injured liver were accurately mapped and quantified without 
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any possibility of crosstalk from in vivo environmental or instrumental factors. Changes in 
cellular ROS and GSH precede changes in conventional biochemical and histological 
assessments in two distinct experimental murine models of liver injury. Therefore, 
monitoring cellular oxidative stress using MPM-FLIM has significant implications for high-
accurate, spatially configured and quantitative assessment of metabolic status and drug 
response.  
        3. The in vivo fate of administered mesenchymal stem cells (MSCs) has been 
visualised using MPM to predict the treatment efficacy of liver cirrhosis (Chapter 5). A 
physiologically-based kinetic model was developed to characterise the disposition of 
administered MSCs based on direct visualization of cell spatiotemporal disposition by 
MPM. This model was further validated with multiple external datasets, indicating potential 
inter-route and inter-species predictive capability. These results suggest that the targeting 
efficiency of MSCs is determined by the lung retention and interaction between MSCs and 
target organs, including cell arrest, depletion and release. By adapting specific 
parameters, this model can be easily applied to abnormal conditions or other types of 
circulating cells for designing treatment protocols and guiding future experiments. 
 
6.2 Future Directions 
        A better understanding of the liver anatomy, physiology and pharmacology is 
necessary for developing new diagnostic and therapeutic strategies for liver diseases. This 
fundamental knowledge can be obtained using various techniques, among which the 
dynamic imaging tools provided by MPM has emerged as a very powerful option to 
researchers. FLIM adds the abilities of MPM to detect environmental changes and 
differentiate fluorophores from biological background according to their lifetimes. Limited 
infiltration depth is one of the most significant limitations of MPM. Normally, the imaging 
depth is hundreds of micrometers in MPM. Thus early diseases arising deep in the liver 
tissue are difficult to be diagnosed with this technique. We anticipate that in the near future 
the penetration depths of MPM will be further increased, and new infrared dyes will be 
developed with longer excitation wavelengths that penetrate more deeply due to less 
absorption and scattering. 
        Although most of the aforementioned researches are based on animal studies, MPM 
has already been applied to clinical settings to diagnose and assess liver diseases [1]. 
Miniaturised laser scanning microscope has been developed, which allows minimal 
invasive imaging of the liver through keyhole incisions [2]. Endoscope coupled with MPM 
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has also been developed, which can image the liver through small surgical incision or 
intrahepatic bile duct as endoscopic retrograde cholangiopancreatography [3]. These 
minimal invasive imaging techniques have provided the possibility of in vivo imaging the 
human liver. Therefore, we anticipate that in the near future MPM will be evaluated from 
bench to bedside, and especially be applied to endoscopic or laparoscopic systems, 
leading to a deep understanding of the anatomy, physiology and pharmacology of the 
human liver. 
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Appendices 
 
Appendix 1 
 
PBK model code for intravenous injection of MSCs in Chapter 5 
 
 
STARTTIME= 0 
STOPTIME=24 
DTMAX = 0.0005 
DTOUT =0.01 
 
; Physiological constants 
BW   = 0.02  ; body weight kg 
 
;dose 
IV = 500000 
 
{-------Organ volumes as percentages of body weight BW---------} 
VLC=0.0549                                  ; Liver volume fraction; Brown et al, 1997 
VLuC=0.007                                   ; Lung volume fraction; Brown et al, 1997 
VBoC=1-(VLC+VKC+VSC+VBloodC)    ; Body volume fraction 
VKC=0.0167                                  ; Kidney volume fraction; Brown et al. 1997 
VSC=0.005               ; Spleen volume fraction; Calculated from Davies and Morris 1993 
VHC=0.004               ; Heart volume fraction; Calculated from Davies and Morris 1993 
VBloodC=0.085            ; Blood volume fraction; Calculated from Davies and Morris 1993 
 
{------------Organ volumes (L)-------------------} 
VBlood=VBloodC*BW 
VL=VLC*BW     ; Liver 
VLu=VLuC*BW   ; Lung             
VS=VSC*BW   ; Spleen             
VBo=VBoC*BW   ; Muscle (Body)                  
VK=VKC*BW   ; Kidney                  
VH=VHC*BW   ; Heart                  
VA = 0.2*VBloodC*BW    ; arterial blood 
VV = 0.8*VBloodC*BW    ; venous blood 
 
; Organ blood Volumes 
VLuVES = 0.5*Vlu    ; lung (L) 
VLVES = 0.31*VL    ; liver (L) 
VSVES = 0.17*VS    ; spleen (L) 
VKVES = 0.24*VK    ; kidney (L) 
VHVES = 0.26*VH    ; heart (L) 
VBoVES = 0.04*VBo ; body (L) 
 
QCC=16.5; Cardiac output constant, calculated from Davies and Morris, 1993 
 
{--------Blood flow to organs/tissues as percentages of cardiac output QCC------} 
QLC=0.161                              ; Liver blood flow fraction; Brown et al, 1997. 
QKC=0.091                              ; Kidney blood flow fraction; Brown et al, 1997 
QSC=0.01125                           ; Spleen blood flow fraction; calculated from Davies and Morris, 1993 
QHC=0.035                              ; Heart blood flow fraction; Brown et al, 1997 
QBoC=1-(QLC+QSC+QKC+QHC)         ; Body blood flow fraction; this compartment designated "Body" 
 
{------------Organ/tissue blood flows (L/hr)------------------} 
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QC=QCC*BW^0.75 
QLu=QC                        ; Lung 
QL=QLC*QC                       ; Liver 
QS=QSC*QC                            ; Spleen 
QBo=QBoC*QC                              ; Body 
QH=QHC*QC                                     ; Heart 
QK=QKC*QC                                        ; Kidney 
 
; Physico-chemical parameters 
PLu = 742.733   ; lung:blood 
PL = 262.699  ; liver:blood 
PS = 1633.24  ; spleen:blood 
PK = 305.351  ; kidney:blood 
PH = 3.097  ; heart:blood 
PBo = 6.765  ; body:blood 
 
; Biochemical parameters (elimination rate constant) 
 
KBelimination = 0.636  
KLuelimination = 0.0589  
KLelimination = 0.06   
KSelimination = 0.002 
KKelimination = 0.151 
KHelimination = 0.039 
KBoelimination = 0.148 
 
; Biochemical parameters (capillary related constant) 
 
KLuCAPrelease = 0.108        ; Lung 
KLuCAPentrap = 5.434 
KLCAPrelease = 0.066        ; Liver 
KLCAPentrap = 1.395 
KSCAPrelease = 0.856        ; Spleen 
KSCAPentrap = 0.608 
KKCAPrelease = 0.054        ; Kidney 
KKCAPentrap = 1.727 
KHCAPrelease = 0.016        ; Heart 
KHCAPentrap = 1.251 
KBoCAPrelease = 0.957        ; Body 
KBoCAPentrap = 0.143 
 
; Venous blood concentration 
d/dt (AV)  = (QL*CVL+ QS*CVL + QK*CVK + QH*CVH + QBo*CVBo)-(QC*CV) - KBelimination*VV*CV 
init AV = IV 
CV = AV/VV 
 
; Arterial blood concentration 
d/dt (AA)  = QC*(CVLu-CA) 
init AA = 0 
CA = AA/VA 
 
; Lung 
d/dt (ALuVES) = QLu*(CV-CVLu) + KLuCAPrelease*ALuCAP - KLuCAPentrap*ALuVES 
init ALuVES = 0 
CLuVES = ALuVES/VLuVES 
CVLu = CLuVES/PLu 
 
d/dt (ALuCAP) = KLuCAPentrap*ALuVES - KLuCAPrelease*ALuCAP - KLuelimination* ALuCAP 
init ALuCAP = 0 
CLung = (ALuVES+ALuCAP)/VLu 
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; Liver 
d/dt (ALVES) = QL*CA+QS*CVS-(QL+QS)*CVL + KLCAPrelease*ALCAP - KLCAPentrap*ALVES 
init ALVES = 0 
CLVES = ALVES/VLVES 
CVL = CLVES/PL 
 
d/dt (ALCAP) = KLCAPentrap*ALVES - KLCAPrelease*ALCAP- KLelimination* ALCAP 
init ALCAP = 0 
CLiver = (ALVES+ALCAP)/VL 
 
; Spleen 
d/dt (ASVES) = QS*(CA-CVS) + KSCAPrelease*ASCAP - KSCAPentrap*ASVES 
init ASVES = 0 
CSVES = ASVES/VSVES 
CVS = CSVES/PS 
 
d/dt (ASCAP) = KSCAPentrap*ASVES - KSCAPrelease*ASCAP- KSelimination* ASCAP 
init ASCAP = 0 
CSpleen = (ASVES+ASCAP)/VS 
 
; Kidney 
d/dt (AKVES) = QK*(CA-CVK) + KKCAPrelease*AKCAP - KKCAPentrap*AKVES 
init AKVES = 0 
CKVES = AKVES/VKVES 
CVK = CKVES/PK 
 
d/dt (AKCAP) = KKCAPentrap*AKVES - KKCAPrelease*AKCAP- KKelimination* AKCAP 
init AKCAP = 0 
CKidney = (AKVES+AKCAP)/VK 
 
; Heart 
d/dt (AHVES) = QH*(CA-CVH) + KHCAPrelease*AHCAP - KHCAPentrap*AHVES 
init AHVES = 0 
CHVES = AHVES/VHVES 
CVH= CHVES/PH 
 
d/dt (AHCAP) = KHCAPentrap*AHVES - KHCAPrelease*AHCAP- KHelimination* AHCAP 
init AHCAP = 0 
CHeart = (AHVES+AHCAP)/VH 
 
; Body 
d/dt (ABoVES) = QBo*(CA-CVBo) + KBoCAPrelease*ABoCAP - KBoCAPentrap*ABoVES 
init ABoVES = 0 
CBoVES = ABoVES/VBoVES 
CVBo = CBoVES/PBo 
 
d/dt (ABoCAP) = KBoCAPentrap*ABoVES - KBoCAPrelease*ABoCAP- KBoelimination* ABoCAP 
init ABoCAP = 0 
CBody = (ABoVES+ABoCAP)/VBo 
 
AT = AV + AA + ALuVES+ALuCAP + ALVES+ALCAP + ASVES+ASCAP + AKVES+AKCAP + 
AHVES+AHCAP + ABoVES+ABoCAP 
 
ALu= ALuVES+ALuCAP 
AL= ALVES+ALCAP 
AS= ASVES+ASCAP 
AK = AKVES+AKCAP 
AH= AHVES+AHCAP 
ABo= ABoVES+ABoCAP 
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